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I.  Introduction 
 
 
 
A.  Statement of Problem 
 
The structural integrity of bone is dependent upon a balance between the 
activity of bone-resorbing osteoclasts and bone-forming osteoblasts [33, 34].  
Through this remodeling process, bone is constantly degraded and replaced with 
new bone.  As humans age, osteoblast activity begins to diminish due to reduced 
reproductive and biosynthetic potential [35].  The resulting imbalance in 
osteoblast to osteoclast activity results in local or systemic bone loss called 
osteoporosis [36], which affects 28 million Americans [37].  As one of the 
prominent health problems associated with aging, osteoporosis is most prevalent 
in post-menopausal women as a result of decreased estrogen levels, but is also 
common in aging men.  A number of therapeutic approaches are available to 
relieve the symptoms of osteoporosis, however, most target osteoclasts to 
prevent further bone loss (i.e., raloxifene, EVISTA; alendronate FOSAMAX; 
calcitonin MIACALCIN) [38].  Another approach is to stimulate the formation of 
bone by targeting the proliferation, differentiation, and activity of osteoblasts [39] 
using teriparatide PTH 1-34 (FORTEO).  The hormone melatonin has recently 
been shown to enhance osteoblast differentiation in animal cell models [43].  The 
goals of this project are therefore to determine whether melatonin enhances 
osteoblast differentiation in a human cell model, and if so, determine the 
signaling pathways melatonin utilizes to cause these enhancing effects.   
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B.  Literature Survey 
1.  Synthesis of Melatonin 
The peptide melatonin is the principle hormone produced from the pineal 
gland through a four step enzymatic transformation originating with the aromatic 
amino acid tryptophan.  Tryptophan is transported into the brain through an 
active uptake process specific to large, neutral amino acids [1, 2].  Once inside 
the brain, tryptophan is hydroxylated by tryptophan hydroxylase, to form 5-
hydroxytryptophan and rapidly decarboxylated by aromatic amino acid 
decarboxylase to form serotonin.  The pineal gland is located along the roof of 
the thalamus, separated from the brain by the blood brain barrier.  Despite its 
separation from the brain, the pineal gland contains all of the enzymes necessary 
to produce serotonin and has 50 times more serotonin content than the entire 
brain [1].  Inside the pineal gland, melatonin is synthesized from serotonin by N-
acetyltransferase activity to form N-acetyl serotonin, which is acted on by 5-
hydroxy indole O-methyltransferase to form melatonin [1, 2].   
       
                                             Melatonin 
The production of N-acetyltransferase, the rate-limiting enzyme necessary 
to convert serotonin to melatonin, is modulated by both lighting conditions and 
circadian oscillation patterns [2].  Production of N-acetyltransferase is 15 to 30-
fold higher during periods of darkness [3] and light exposure as brief as 1 min 
reduces N-acetyltransferase activity by over 50% [4].  The pineal gland’s 
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sensitivity to lighting conditions is detected by the eye and occurs through central 
innervation [5].  Light sensitivity is maintained despite interruption of the 
sympathetic innervation via removal of the superior cervical ganglia [5].  
Independent of lighting conditions, N-acetyltransferase production is also 
influenced via a cyclic daily rhythm [6].  Like N-acetyltransferase production, the 
clock genes Per1 and Cry2 in the rat pineal gland are expressed in a circadian 
fashion and regulated by the circadian-driven changes in norepinephrine [7].  
Within the chicken pineal gland, the enzymes necessary for melatonin synthesis, 
namely tryptophan hydroxylase, arylalkylamine-N-acetyltransferase, and 
hydroxyindole-O-methyl-transferase mRNA are expressed in a circadian fashion 
that persists during periods of constant darkness [8].  Furthermore, in blind 
mammals, N-acetyltransferase activity is continuously produced on a cyclic 
pattern, but is independent of lighting conditions [1].  
Both the light-dark cycle and circadian inductions in N-acetyltransferase 
production are mediated through sympathetic stimulation [3, 6].  During periods 
of darkness, norepinephrine containing sympathetic nerves are stimulated, 
inducing the release of norepinephrine from nerve endings within the pineal 
gland, whereupon it binds to β1-adrenergic receptors coupled to Gs proteins, or 
α1-adrenergic receptors coupled to Gq proteins [9, 10].  Upon β1 receptor 
activation, Gs proteins activate adenylyl cyclase located within the 
transmembrane.  Once activated, adenylyl cyclase stimulates the conversion of 
adenosine triphosphate to cyclic AMP production and subsequent allosteric PKA 
activation.  Additionally, upon α1 receptor activation, Gq activates PKC activity, 
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causing an increased release of Ca2+ from the endoplasmic reticulum followed by 
a rapid influx of Ca2+ into the pinealocyte [10].  The induction of activated PKA 
and increased Ca2+ concentration leads to the activation of CREB transcription 
factors, which induces the transcriptional production of N-acetyltransferase 
enzyme.  While both β1 and α1 adrenergic receptor activation stimulates N-
acetyltransferase production, β1 receptor can independently stimulate N-
acetyltransferase production [9], while α1 receptor activation preferentially 
stimulates serotonin release from the pineal gland [11].   
2.  Metabolism of Melatonin 
Melatonin metabolism occurs primarily through conjugation reactions 
(~70%) and secondarily through oxidation (~15%) or alternatively, it is excreted 
unchanged (15%) [12].  Prior to conjugation, melatonin must be hydroxylated to 
form 6-hydroxy-melatonin or demethylated to form N-acetyl-serotonin, which are 
then conjugated with sulphur or glucoronide to form the principle melatonin 
metabolites, 6-hydroxy-melatonin sulphate or N-acetyl-serotonin, respectively 
[12].  Hydroxylation and demethylation of melatonin is mediated through the high-
affinity cytochrome p450 enzyme isoform CYP1A2 within the liver [13].  
Alternatively, oxidative metabolism of melatonin metabolism may proceed 
through two different enzymes, with the route dependent upon the presence or 
absence of the peroxide cofactor [14].  When peroxide is present, melatonin is 
oxidized via indoleamine 2, 3-dioxygenase, which is also capable of tryptophan 
and serotonin oxidation.  When peroxide is absent, indoleamine 2, 3-
dioxygenase is incapable of oxidizing melatonin, leaving myeloperoxidase as the 
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sole enzyme capable of oxidizing melatonin by cleaving the indole moiety.  
Potential metabolites formed during melatonin oxidation are N1-acetyl-N2-formyl-
5-methoxykynuramine (AFMK) and N1-acetyl-5-methoxykynuramine (AMK).  Both 
metabolites have demonstrated antioxidant and free radical scavenging abilities 
that may further amplify melatonin’s antioxidant actions [15].   
3.  Subtypes of the Melatonin Receptor 
Melatonin may act through a variety of mediators, including melatonin G-
protein coupled receptors, quinone reductase coupled melatonin receptors, or 
alternatively, melatonin can act independently of a receptor due to its lipophilic 
nature [16] and potent antioxidant properties [15, 17].  Two distinct subtypes of 
melatonin seven transmembrane G protein-coupled receptors, designated MT1 
and MT2 have been cloned and characterized.  Both G protein-coupled receptors 
are coupled to Gi and Gq proteins [18, 31, 32], that upon activation, induces an 
inhibition of adenylyl cyclase to reduce cyclic AMP levels (0.1 pM – 1 nM) or 
phospholipase C activation, which hydrolyzes phosphatidylinositol 4, 5-
bisphosphate (PIP2) to form inositol 1, 4, 5-trisphosphate and diacylglycerol, 
respectively (1 nM – 1 µM) [19, 32].  The MT1 melatonin receptor is widely 
dispersed throughout the body, including the suprachiasmatic nucleus (SCN), 
pars tuberalis, retina and cardiac blood vessels, where physiologically, melatonin 
inhibits neuronal firing [20], inhibits prolactin secretion on a circadian basis [21], 
modulates retinal physiology [22], and dilates blood vessels, respectively [30, 
32).  Alternatively, the MT2 melatonin receptor, in addition to coupling with Gi or 
Gq proteins, is also able to inhibit the soluble guanylyl cyclase pathway [19, 32).  
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The MT2 melatonin receptor is localized within the SCN, cardiac vessels, kidney, 
ovary, and retina where it modulates circadian rhythms, constricts blood vessels, 
differentiates the nephron [23], induces folliculogenesis [24], and inhibits 
dopamine release [25], respectively.  A second type of melatonin receptor, 
designated MT3, has more recently been identified in hamster kidney or ovary 
cells that shares 95% homology to the human quinone reductase 2 enzyme [26].   
More recent findings indicate the MT3 binding site is diversely present in a wide 
array of mammals and tissue, with highest receptor amounts and quinone 
reductase enzymatic activity uniformly detected in the liver and kidney [27].  
Functionally, the quinone reductase 2 enzyme is responsible for the reduction of 
quinones to stable intermediates that can be later conjugated and excreted, thus 
preventing the production of highly reactive oxygen species [28].  Additionally, 
quinone reductase 2 has demonstrated antioxidant abilities that may partially 
explain melatonin’s observed antioxidant effects [17].  Physiologically, MT3 
melatonin receptor activation has been shown to decrease intraocular pressure 
and inhibit adhesion of leukocytes [29, 30].     
4.  Melatonin and Osteoporosis 
Mounting evidence associates the age-related decreases in plasma 
melatonin to increased susceptibility to osteoporosis [40].  Melatonin plasma 
levels are significantly lower in humans past the age of 50 compared to pre-
pubescent individuals [41-43] and these age-related reductions may lead to the 
increased occurrence of osteoporosis throughout adulthood [40, 43-45]. Recently 
Turgut and colleagues [46] showed that pinealectomized chickens had 
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significantly lower bone mineral density at the cervical vertebral body compared 
with nonpinealectomized control animals.  Pinealectomized chickens also had a 
plateau-shaped density histogram between the fourth and seventh cervical 
vertebra indicating an inactive osteoblast population compared with 
nonpinealectomized animals with higher density bone tissues.  Histological 
changes were also noted in the pinealectomized chickens, as the total number of 
osteocytes were significantly lower than control, suggesting melatonin enhances 
osteocyte proliferation in the cervical vertebra.  Several animal models have 
reported that melatonin has a preventive effect of idiopathic scoliosis [46-50].  
This demonstrated correlation appears independent of posture and gravity, 
because pinealectomized Atlantic salmon have abnormal spinal curves, reduced 
mechanical properties, and reduced vertebral mineral content [47].  The effect of 
melatonin on cellular differentiation has stimulated interest in its role in 
osteoporosis.   
Melatonin accumulation and/or synthesis within the bone marrow has 
been widely documented in vivo, where it may act to enhance bone formation 
[51-54].  Elevated melatonin concentrations occur in the bone marrow of rats, 
with night-time bone marrow concentrations approximately twice as high as the 
peripheral blood [51].  Exogenously administered melatonin collects within the 
bone marrow against a plasma concentration gradient, suggesting the presence 
of melatonin binding proteins.  Although lower than pineal intact rats, elevated 
bone marrow melatonin concentrations persist in long-term pinealectomized rats.  
These data indicate that a portion of melatonin present in the bone marrow may 
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come from an extrapineal source.  Additionally, enzymes necessary to convert 
serotonin to melatonin, namely N-acetyltransferase (NAT), but not hydroxyindole-
O-methoxyltransferase (HIOMT) activity are present in the bone marrow cells.  
Various potential mechanisms exist regarding how melatonin enhances bone 
formation.   
Melatonin is implicated in bone development through both the suppression 
of bone-resorbing osteoclast cells [45, 54], possibly via its free radical 
scavenging properties [55-59], and through the enhancement of bone producing 
osteoblast differentiation [43, 44].  Melatonin causes a dose-dependent reduction 
in both osteoclastogenesis and osteoclast activity by reducing the number of 
resorption pits and average pit area/pit in mouse bone marrow cells possibly 
through the down-regulation of receptor activator of NF-κB ligand (RANKL) and 
hence NF-κB activity [45].  Furthermore, in goldfish scales, melatonin significantly 
suppresses osteoclast activity, observed via a reduction in tartrate-resistant acid 
phosphatase (TRACP) activity following six hour incubation with 10 nM, 1 µM, 
and 10 µM melatonin [54].   
Besides having effects on osteoclasts, several studies show that 
melatonin enhances bone formation through the stimulation of bone-producing 
osteoblast cells [43, 44].  Melatonin’s ability to directly promote osteoblast 
maturation was first demonstrated in pre-osteoblast and rat osteoblast-like 
osteosarcoma cells, [43] where low (10 nM) concentrations of melatonin increase 
the mRNA levels of several genes expressed in osteoblasts including alkaline 
phosphatase, bone sialoprotein (BSP), osteopontin, and osteocalcin.  
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Furthermore, these osteoblast effects are mediated through melatonin 
transmembrane receptors, as exposure to pertussis toxin or the melatonin 
receptor antagonist luzindole significantly reduces bone sialoprotein and alkaline 
phosphatase expression [43].  Similar results are reported in clinically relevant 
human bone cells, in which micromolar concentrations of melatonin significantly 
increase procollagen type I c-peptide production in a concentration-dependent 
manner [44].   
Even though a majority of the reports show positive effects on bone 
formation, in some studies, inverse correlations between melatonin and bone 
formation are observed.  For example, melatonin suppresses the activity of 
osteoblast cells, possibly via the down-regulation of estrogen receptor and 
insulin-like growth factor (IGF)-1 mRNA expression.  Ostrowska and colleagues 
report similar findings, as alkaline phosphatase (ALP), carboxyterminal 
propeptide of type I procollagen (PICP), and cross-linked carboxyterminal 
telopeptide of type I collagen (ICTP) were negatively correlated with endogenous 
melatonin concentrations in male Wistar rats [58].  Additionally, pinealectomy in 
male Wistar rats increases the levels of bone metabolism biomarkers, including 
alkaline phosphatase activity, carboxyterminal propeptide of type I procollagen, 
and cross-linked carboxyterminal telopeptide of type I collagen [59].  Similarly, 
melatonin and estradiol co-exposure lowers urinary deoxypyridinoline, a marker 
of bone resorption in ovariectomized rats [60].   
5.  Signal Transduction Mechanisms Mediating Osteoblast Differentiation 
The underlying signal transduction mechanism(s) responsible for 
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melatonin’s effects on osteoblast differentiation have yet to be elucidated, but 
evidence suggests that the mitogen activated protein kinase (MAP-K) signal 
transduction pathway may be involved [61-67].  Supporting this, Rawadi and co-
workers [65] find that osteoblast differentiation is dependent upon MEK (1/2) 
activation, as selective MEK inhibitors (PD98059, U0126) block osteoblast 
differentiation in either a murine mesenchymal stem cell line or a pluripotent 
murine myoblast cell line induced by a phosphodiesterase inhibitor.  In human 
adult mesenchymal stem cells (hAMSCs), UO126 co-incubated with EGF ligand, 
completely eliminates phosphorylation of ERK1 and ERK2, with subsequent 
inhibition of the hAMSC converting to the osteoblast [67].  Similarly, Suzuki and 
colleagues [63] find that the MAP-Ks, ERK and p38, and potentially JNK, 
regulate different stages of osteoblast cell proliferation and differentiation.    
Phosphorylation of the MAP-K signaling cascade may also be mediated 
by the epidermal growth factor receptor (EGFR).  In this regard, transactivation of 
the EGFR by G-protein coupled receptors may occur through a matrix 
metalloproteinase-mediated proteolytic release of EGF.  In human adult 
mesenchymal stem cells, EGFR induces the phosphorylation of ERK 1/2 and 
modulates osteoblast differentiation [67].  Probing further into the signaling 
mechanisms that underlie GPCR-mediated activation of ERK, it is found that G-
proteins and matrix metalloproteinases may be involved.  For example, using 
PC12 cells, Piiper and colleagues [68] demonstrate that EGFRs, activated by 
increases in cAMP, induce ERK 1/2 phosphorylation that is reversed in the 
presence of the EGFR inhibitor, PD165393.  In addition, using renal mesangial 
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cells, the GPCRs 5-hydroxytryptamine2A, lysophosphatidic acid, angiotensin AT1 
and bradykinin B2, induce the phosphorylation of the EGFR and ERK through a 
PKC-dependent pathway [69].  Also, transactivation of the EGFR by G proteins is 
mediated by the Gβγ subunit in recombinant cells [70], or matrix 
metalloproteinases in transgenic murine osteoblasts [71].  Subsequent to Gi 
protein activation via lysophosphatidic acid exposure, it is shown that the Gβγ 
subunit induces the phosphorylation of Shc adapter proteins; proteins that bind to 
tyrosine phosphoproteins like EGFRs.  Phosphorylation of the EGFR and Shc 
adapter protein binding is reversible following cellular expression of dominant 
negative kinase-inactive mutants of c-Src.  In a different study, Gi-protein coupled 
lysophosphatidic acid receptors induce ERK activation, and this increase in ERK 
activity coincided with EGFR phosphorylation [71].  EGFR phosphorylation is 
sensitive to matrix metalloproteinase inhibition, indicating EGFR transactivation 
occurs via proteolytic EGF ligand liberation [71].  Additionally, proteolysis of 
heparin-bound EGF ligand is shown to induce the autophosphorylation of EGFR 
and subsequent ERK activation.  Taken together, these studies suggest 
melatonin-mediated changes in MEK 1/2 activity may occur through matrix 
metalloproteinase-mediated transactivation of the epidermal growth factor 
receptor.   
A multifunctional group of proteins may facilitate melatonin mediated 
activation of epidermal growth factors and/or the MAP-K signaling cascade.  β-
arrestin-1 and -2 are ubiquitously distributed proteins classically involved with 
GPCR desensitization and clathrin-dependent internalization following prolonged 
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agonist exposure [72, 73].  As a means of stimulus-driven homologous 
desensitization, activated GPCRs are readily phosphorylated on serine or 
threonine residues by G protein-coupled receptor kinases (GRK), inducing their 
translocation to the plasma membrane and binding of β-arrestin-1 and β-arrestin-
2 proteins to the carboxy terminal region of the GPCR [74].  Once bound, β-
arrestin induces the uncoupling of the GPCR from the G-protein and targets the 
receptor for clathrin-dependent receptor internalization and possible degradation 
[69].  Besides the protein’s receptor regulatory actions, β-arrestin has more 
recently been shown to act as a scaffolding protein; connecting downstream 
proteins to the receptor to facilitate signaling [75-79] and causing the activation of 
the MAP-K cascade [74, 79].  Through an intricate set of experiments, Luttrell 
and colleagues [76] found that angiotensin exposure induces the formation of 
multi-protein complexes, which include the angiotensin II type 1a (AT1aR) 
GPCR, β-arrestin-2, and the complete set of MAP-K proteins, cRaf-1, MEK1, and 
ERK2.   
The functional consequences of GPCR desensitization and signaling 
ability is highlighted in GRK mutant cells.  Osteoblastic cells expressing dominant 
negative GRK mutants reduce cellular proliferation and impair tyrosine kinase-
mediated activation of the MAP-K signaling cascade [80].  Thus, impeding 
receptor phosphorylation and subsequent β-arrestin binding is detrimental to 
cellular function.   
Interestingly, β-arrestin scaffolding proteins have also been implicated in 
both the activation and translocation patterns of MAP-K into both the cytosol [76] 
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and nuclear compartments [74].  The translocation patterns of ERK (i.e. cytosol 
vs. nucleus) may dictate the response of the cell to a stimulus.  Because the 
MAP-K pathway is intimately involved in proliferative and differentiation 
responses, then the distribution of ERK to various cellular compartments may 
determine which of these responses will be affected.  Unique ERK translocation 
patterns within a cell in response to different stimuli are demonstrated in several 
studies.  Angiotensin exposure induces the redistribution of activated ERK2 into 
endosomal vesicles within the cytosol, while in COS-7 cells transfected with β1 or 
β2 adrenergic receptors, β-arrestin binding induces activated ERK translocation 
into the nucleus [74].  The β-arrestin-mediated variance within translocation 
patterns between the cytosol and nucleus may depend on the stability of the 
GPCR-β-arrestin interaction [79].  Stable GPCR-β-arrestin complexes enhance 
the activation of ERK within the cytosol, whereas transient receptor-β-arrestin 
complexes result in a decrease in ERK-P within the nucleus.  The reduction in 
ERK-P within the nucleus correlates with a decrease in transcriptional and 
mitogenic responses, indicating that the stability of the GPCR-β-arrestin complex 
influences both ERK translocation and ERK-mediated responses.   
β-Arrestin ubiquitination appears to regulate the receptor internalization 
and scaffolding properties of the protein.  Following β2 adrenergic receptor 
activation, Mdm2 and E3 ubiquitin ligase binds to and ubiquitinates β-arrestins.  
Inhibition of the Mdm2-mediated β-arrestin ubiquitination prevents both receptor 
internalization and enhances translocation of activated ERK into the cytosol [81-
83].  The melatonin GPCR may similarly utilize β-arrestin to facilitate homologous 
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receptor internalization and/or scaffolding with the MAP-K signaling cascade.   
6.  Human Adult Mesenchymal Stem Cell Model 
Human adult mesenchymal stem cells (hAMSCs) are bone marrow-
derived multipotent precursors for a variety of mesoderm cell lineages [84].  
Current cell culture techniques, through a utilization of specific growth factors, 
are known to induce the differentiation of the hAMSCs into chondrocyte, 
adipocyte, or osteoblast terminal cell lines [84-87].  hAMSCs have been shown to 
differentiate into an osteoblast lineage when incubated in a medium containing 
dexamethasone, ascorbic acid, and β-glycerophosphate [85].  Under these 
conditions, ALP enzymatic activity significantly increases following 8 – 12 day 
incubation, with subsequent mineral deposition occurring by 12 – 16 d [85].   
The ability of hAMSCs to differentiate into an osteoblast when incubated with an 
osteogenic inducing medium is maintained throughout passages 1-10 [86].  
Because of their ability to differentiate into terminal mesodermal cells, hAMSCs 
are currently being investigated for their clinical potential in tissue regeneration 
[88-91].  Additionally, the hAMSC model being investigated is clinically 
appropriate, considering the human, non-cancerous origin that has been used in 
other models [43]. 
The goals of this study were to determine if melatonin, acting through 
transmembrane melatonin receptors, enhances human adult mesenchymal stem 
cell differentiation into osteoblasts, and, if so, determine the intracellular signal 
transduction pathways that mediate this process.  Based on previous findings, 
we hypothesized that melatonin, acting through melatonin GPCRs, is able to 
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enhance the differentiation of hAMSC into osteoblasts mediated through the 
transactivation of EGFRs and subsequent stimulation of the MAP-K signaling 
cascade.  
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II.  MATERIALS AND METHODS 
 
 
 
A. Materials and Equipment 
 
1. Facilities 
 
Laboratories – Mellon Hall of Science, Rooms 245, 262, 406, 414 and 454  
 
Office – Mellon Hall of Science, Room 420 
 
2. Cell lines 
 
Human Adult Mesenchymal Stem Cells (HAMSCs) 
Cambrex Bio Science Walkersville, Inc., Walkersville, MD 
 
3. Chemicals and Drugs 
 
Anti-β-Arrestin-1 (Goat), Lot No. D0903 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 
 
Anti-β-Arrestin-2 (Mouse), Lot No. E3105 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 
 
Anti-Epidermal Growth Factor Receptor-Phos (Mouse),  
Lot No. B58671 
Lab Vision Co., Fremont, CA 
 
Anti-Gαi-2 (Rabbit), Lot No. J139 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 
 
Anti-MT1 Receptor (Human) 
Dr. Ralf Jockers, Université Paris VII  
 
Anti-MT2 Receptor (Human) 
Dr. Ralf Jockers, Université Paris VII  
 
Anti-Mitogen Activated Protein Kinase (Rabbit), Lot No. 03J4513 
Sigma Chemical Co., St. Louis, MO 
 
 Anti-Mitogen Activated Protein Kinase-Phos (Rabbit), Lot No. 16 
 Cell Signaling, Beverly, MA 
 
Anti-Mitogen Activated Protein Kinase Kinase (Rabbit),  
Lot No. 78K1039 
Sigma Chemical Co., St. Louis, MO 
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Anti-Mitogen Activated Protein Kinase Kinase-Phos (Rabbit),  
Lot No. 15 
Cell Signaling, Beverly, MA 
 
β-Glycerophosphate, Lot No. 50F-0269 
Sigma Chemical Co., St. Louis, MO 
 
Bromophenol Blue, Lot No. DB102341 
American Bioanalytical, Naticle, MA 
 
Complete Mini protease inhibitor cocktail tablets 
Roche Diagnostics Corp., Indianapolis, IN 
 
3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide; 
thiazolyl blue 
Sigma Chemical Co., St. Louis, MO 
 
Digitonin 
Sigma Chemical Co., St. Louis, MO 
 
Donkey Anti-goat IgG, Horseradish Peroxidase 
Santa Cruz Biotechnology, Inc., Santa Cruz, CA 
 
 DTT, Lot No. 037538 
Fisher Scientific, Pittsburgh, PA 
 
Dulbecco’s Phosphate Buffered Solution, Ca/Mg-free 
Invitrogen, Grand Island, NY 
  
 ECL Anti-mouse IgG, Horseradish Peroxidase linked whole antibody 
 Amersham Biosciences, Piscataway, NJ 
 
 ECL Anti-rabbit IgG, Horseradish Peroxidase linked whole antibody 
 Amersham Biosciences, Piscataway, NJ 
 
 EDTA, Lot No. 113HO862 
Sigma Chemical Co., St. Louis, MO 
 
EGTA, Lot No. 30K5420 
Sigma Chemical Co., St. Louis, MO 
 
Ethanol (95%) 
Prepared from stock, Duquesne University, Pittsburgh, PA 
 
Forskolin, Lot No. 044K7042 
  
18
Sigma Chemical Co., St. Louis, MO 
 
Glycerol (99.9%) 
Sigma Chemical Co., St. Louis, MO 
 
Glycine, Lot No. 70K0069 
Sigma Chemical Co., St. Louis, MO 
 
GM 6001, Lot No. B65127 
Calbiochem, La Jolla, CA 
 
5’-Guanylylimidodiphosphate, Lot No. 064K0163 
Sigma Chemical Co., St. Louis, MO 
 
HEPES, Lot No. 951465 
Fisher Scientific, Pittsburgh, PA 
 
Human Mesenchymal Stem Cell Growth Medium 
Cambrex Bio Science Walkersville, Inc., Walkersville, MD 
 
Human Mesenchymal Stem Cell Osteogenesis Induction Medium 
Cambrex Bio Science Walkersville, Inc., Walkersville, MD 
 
Hydrochloric Acid, Lot No. 983601 
Fisher Scientific, Pittsburgh, PA 
 
Isopropranol (99.5%) 
Fisher Scientific, Pittsburgh, PA 
 
2-[125I]-iodomelatonin (specific activity 2200 Ci/mmol) – Lot No. EG31760 
NEN Dupont, Boston, MA 
 
 KT5720, Lot No. B26653 
 Sigma Chemical Co, St. Louis, MO 
  
 Luzindole, Lot No. 1/13867 
 Tocris , Ballwin, MO 
 
 Magnesium Chloride, Lot No. 27H0828 
 Sigma Chemical Co., St. Louis, MO 
 
 Melatonin, Lot No. 128H0473 
 Sigma Chemical Co., St. Louis, MO 
 
 Methanol (99.9%), Lot No. 60K3751 
 Sigma Chemical Co., St. Louis, MO 
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 Monodansyl Cadaverine, Lot No. 50K3250 
 Sigma Chemical Co., St. Louis, MO 
 
 Nonfat Dry Milk 
 Topco Associates, Inc., Skokie, IL 
 
 Nonidet P-40 
Fisher Scientific, Pittsburgh, PA 
 
 PD168393, Lot No. B27116 
Calbiochem, La Jolla, CA 
 
PD98059, Lot No. B24069 
Calbiochem, La Jolla, CA 
 
 Pertussis toxin, Lot No. 129H1330 
 Sigma Chemical Co., St. Louis, MO 
 
 PhosphoDetect Anti-Epidermal Growth Factor mAb (Mouse) 
Calbiochem, La Jolla, CA 
 
 P-Nitrophenol Phosphate Stock, Lot No. 101K6115 
 Sigma Chemical Co., St. Louis, MO 
 
 Polyethylenimine, Lot No. 78H0692 
 Sigma Chemical Co., St. Louis, MO 
 
 Potassium Chloride, Lot No. 89F-0869 
 Sigma Chemical Co., St. Louis, MO 
  
 Potassium Phosphate Monobasic, Lot No. 113H0292 
 Sigma Chemical Co., St. Louis, MO 
 
 4P-PDOT, Lot No. 1/24467 
 Tocris , Ballwin, MO 
 
 Protein A Agarose Beads, Lot No. 045K1223 
 Sigma Chemical Co., St. Louis, MO 
 
 Rolipram, Lot No. 055K4602 
 Sigma Chemical Co., St. Louis, MO 
 
 Sodium Chloride, Lot No. 041752 
Fisher Scientific, Pittsburgh, PA 
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Sodium Dodecyl Sulfate, Lot No. 064K0163 
Sigma Chemical Co., St. Louis, MO 
 
Sodium Hydroxide, Lot No. 109H0187 
 Sigma Chemical Co., St. Louis, MO 
 
 Sodium Orthovanadate 
 Sigma Chemical Co., St. Louis, MO 
 
 Trichloroacetic Acid 
Sigma Chemical Co., St. Louis, MO 
 
 Triton X-100 
Sigma Chemical Co., St. Louis, MO 
 
 Trizma Base, Lot No. 064K5452 
 Sigma Chemical Co., St. Louis, MO 
 
 Trizma Hydrochloride, Lot No. 49H5402 
 Sigma Chemical Co., St. Louis, MO 
 
4. Materials 
 
Bicinchoninic acid Protein Assay Kit 
Pierce, Rockford, IL 
 
Biomax Light Film 
Eastman Kodak Co., Rochester, NY 
 
BioRad Protein Assay Kit, Lot No. 
BioRad, Hercules, CA 
 
75 cm2 Cell Culture Flask 
Corning Inc., Corning, NY 
 
Compressed Carbon Dioxide 
Air Products, Pittsburgh, PA 
 
Corning 6 Well Tissue Culture Plate  
Corning Inc., Corning, NY 
 
Corning 12 Well Tissue Culture Plate 
Corning Inc., Corning, NY 
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Corning 96 Well Cell Culture Cluster Plate 
Corning Inc., Corning, NY 
 
Correlate-EIA Direct Cyclic AMP Kit 
Assay Designs, Ann Arbor, MI 
 
Cryogenic Vials 
Nalgene, Rochester, NY 
 
DAPI Stain 
Invitrogen, Carlsdad, CA 
 
Disposable Pasteur Pipettes 
Fisher Scientific, Pittsburgh, PA 
 
ECL-Plus 
Amersham Arlingtion Heights, IL 
 
Fisherbrand Redi-TipsTM Disposable Pipet Tips (1, 10, 200 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Glass fiber filters (0.22 µm) 
Schleicher & Schuell, Keene NH 
 
Glass Microscope Slides 
Fisher Scientific, Pittsburgh, PA 
 
22x22 mm Glass Coverslips 
Fisher Scientific, Pittsburgh, PA 
 
Hemacytometer 
American Optical Co., Buffalo, NY 
 
Immobilon Transfer Membranes, Lot No. K2MN4305S 
Millipore Co., Bedford, MA 
 
Labsystem Adjustable Finnpipette, D39077 (1-5 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Labsystem Adjustable Finnpipette, C99511 (200-1000 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Labsystem Adjustable Finnpipette, E08481 (40-200 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Labsystem Adjustable Finnpipette, D33981 (5-40 µl) 
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Fisher Scientific, Pittsburgh, PA 
 
LIVE/DEAD® Viability/Cytotoxicity Kit 
Molecular Probes, Eugene, OR  
 
Microfuge Tubes, (1.5 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Ready Gels, Lot No. L101105G2 
BioRad Laboratories, Hercules, CA 
 
Sigma Diagnostics Alkaline Phosphatase Kit 
Sigma Chemical Co., St. Louis, MO 
 
Sterile Disposable Serological Pipets (5, 10, 25, 50 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Sterile Polystyrene Conical Tubes (15, 50 ml) 
Becton-Dickinson, Lincoln Park, NJ 
 
5. Equipment 
 
Analytical Balance 
Mettler-Toledo Inc., Hightstown, NJ 
 
BioRad Power Pac 3000 
BioRad, Hercules, CA 
 
Cell Harvester 
Brandel Biomedical R&D Labs, Inc., Gaithersburg, MD 
 
Centrific Model 225 Centrifuge 
Fisher Scientific, Pittsburgh, PA 
 
Centrific Model 228 Centrifuge 
Fisher Scientific, Pittsburgh, PA 
 
Cobra II Auto-Gamma Counter 
Packard Instrument Co., Downers Grove, IL 
 
Drummond Pipet Aid 
Drummond Scientific Co., Broomall, PA 
 
Gel Apparatus 
BioRad, Hercules, CA 
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Hot Plate with Stirrer 
Fisher Scientific, Pittsburgh, PA 
  
 
 HTS 7000 Bio Assay Reader 
 Perkin Elmer, Norwalk, CT 
 
Isotemp Incubator 
Fisher Scientific, Pittsburgh, PA 
 
 Kodak M35A X-OMAT Processor 
 Kodak, New Haven, CT 
 
 Laminar Flow Hood 
 Forma Scientific Inc., Marietta, OH 
 
 Nikon Eclipse E600 microscope equipped with fluorescence optics 
 Fryer Co., Inc., Cleveland OH 
  
 Olympus CK2 Light Microscope 
 Olympus, Melville, NY 
 
pH Meter 220 
Corning Inc., Corning NY 
 
Scion Series 7 Image Capture System 
Scion Corporation, Frederick, MD 
 
Tissue Tearor Variable Speed 
Dremel, Racine, WI 
 
Ultracentrifuge, Model L3-50 
Beckman Instruments, Inc., Palo Alto, CA 
 
UV/VIS Spectrophotometer, Model 6405 
Jenway, Essex, UK 
 
Water-Jacketed Incubator 
Forma Scientific Inc., Marietta, OH 
 
Weighing Balance 
Denver Instrument, Denver, CO 
 
6. Computer Software 
 
Adobe Photoshop Version 5.0 
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Adobe Systems, Seattle, WA 
 
AssayZap Version 2.51 
Biosoft, Ferguson, MO 
 
GraphPad Prism 3.0 
GraphPad, San Diego, CA 
 
Microsoft Excel, Microsoft Office 2003 
Microsoft Corporation, Orem, UT 
 
Microsoft Word, Microsoft Office 2003 
Microsoft Corporation, Orem, UT 
 
NIH-Image Version 1.62 
Bethesda, MD 
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B.  Methodology and Procedures 
1.  Cells and Cell Culture 
Multipotent human adult mesenchymal stem cells (hAMSCs) capable of 
differentiating into osteoblasts [84 - 87] were used to evaluate melatonin’s ability 
to enhance osteoblast differentiation.  Human adult mesenchymal stem cells 
were purchased from Cambrex (Walkersville, MD) and maintained at 37°C, in 5% 
CO2, and 90% humidity.  Cells were passaged at 80% confluence.  Cells 
(passage 5-10) were then seeded at a initial density of 3x103 cells/cm2 [85] in 6 
or 12 well plates, or T-75 plates in basal growth medium (Cambrex, Walkersville, 
MD), or osteogenic medium (Cambrex, Walkersville, MD) containing ascorbate, 
dexamethasone, and β-glycerophosphate for the indicated times.      
 
2.  Treatment Groups 
Four treatment groups (OS-M-, OS-M+, OS+M-, OS+M+) were used 
throughout this study to analyze melatonin’s effect on hAMSC differentiation into 
osteoblasts.  Two of the treatment groups consisted of basal growth medium 
(OS-) containing either 0.05% ethanol vehicle (OS-M-) or 50 nM melatonin (OS-
M+) (Sigma, St. Louis, MO).  The basal growth medium was intended to promote 
hAMSC proliferation but not induce differentiation into an osteoblast.  Treatments 
lasted for 10 days and were conducted to determine if melatonin could stimulate 
osteoblast differentiation independently from osteogenic medium.  The remaining 
two groups (OS+M-, OS+M+) were exposed to osteogenic medium (OS+) in the 
absence (OS+M-) or presence (OS+M+) of melatonin to promote osteoblast 
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differentiation.  These studies were conducted for 10 days to determine if 
melatonin could modulate osteogenic induced differentiation of hAMSCs into 
osteoblasts.   
 
3.  Melatonin Binding Assays 
To determine whether or not melatonin binding sites were modified 
following hAMSC differentiation into an osteoblast, 2-[125I]-iodomelatonin 
saturation analysis was performed as described previously [64].  Cells were 
seeded at a density of 3x103 cells/cm2 in T-75 flasks and exposed for 5 or 10 
days to (OS-M-), (OS-M+), (OS+M-), (OS+M+).  Next, cells were washed five 
times with 10 ml of phosphate-buffered saline (PBS) (Invitrogen, Grand Island, 
NY) without calcium chloride or magnesium chloride, lifted from the plates using 
10 mM KPO4, 1 mM EDTA at pH 7.4, and pelleted by centrifugation (500 x g, 5 
min).  The cells were then resuspended in cold Tris-HCl (50 nM, pH 7.4) buffer 
containing 1 X complete mini protease inhibitors (Roche Diagnostics, Mannheim, 
Germany), and aliquoted into tubes containing concentrations of 2-[125I]-
iodomelatonin (2,200 Ci/mmole; NEN/DuPont, Boston, MA) ranging from 0-1 nM 
in the absence or presence of 1 µM melatonin.  The reactions were incubated for 
1 h at room temperature and then terminated by ice-cold Tris-HCl buffer (50 nM, 
pH 7.4).  Filtration was performed using glass fiber filters (0.22 µm), presoaked in 
0.5% polyethylinimine, and using a Brandel Cell Harvester.  Each filter was 
washed twice with 5 ml Tris-HCl buffer.  Radioactivity was counted using a 
gamma counter.  Saturation analysis was performed using GraphPad Prism 
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Software© (GraphPad Inc., San Diego, CA).  The affinity (KD) and density (Bmax) 
of 2-[125I]-iodomelatonin binding were determined for each experiment performed 
within a treatment group and then averaged.  The average KD and Bmax values 
were then compared between treatment groups.  Statistics were performed using 
one-way ANOVA followed by a Newman-Keuls post hoc t-test where significance 
was set at p<0.05.   
 
4.  Cyclic AMP Measurement 
To determine whether melatonin receptor function changed following 
hAMSC differentiation, cAMP assays were performed using a direct cyclic AMP 
enzyme immunoassay kit (Assay Designs, Inc., Ann Arbor, MI).  Briefly, hAMSCs 
were plated at a density of 3x103 cells/cm2 and exposed to (OS-M-), (OS-M+), 
(OS+M-), (OS+M+) for 10 days.  Next, cells were washed and then exposed to 
basal growth medium (no serum) containing rolipram (30 µM) and/or forskolin 
(100 µM) and appropriate concentrations of melatonin (1 fM – 1 µM) for 10 min.  
Concentration-response curves were generated using Prism software.  Potency 
(IC50) and efficacy (maximum inhibition) values were obtained from each 
individual curve within a treatment group and then averaged.  The average IC50 
and maximum inhibition values were calculated for each treatment group and 
then compared between groups. Statistics were performed using an unpaired t-
test where significance was set at p<0.05.   
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5.  MTT Assay 
To assess whether melatonin and osteogenic medium affected hAMSC 
proliferation, cellular proliferation was assessed using 3-[4, 5-dimethylthiazol-2yl]-
2,5-diphenyltetrazolium bromide; thiazolyl blue (MTT, Sigma, St. Louis, MO) 
assay after 7-day exposure to (OS-M-), (OS-M+), (OS+M-), (OS+M+).  This time 
point was chosen to ensure that over-confluence of cells did not obscure the 
proliferation results.  The MTT assay is dependent on cellular reduction of MTT 
by the mitochondrial dehydrogenase in living cells producing a formazan product 
that represents the number of living cells.  The amount of formazan product 
produced from the MTT assay was solubilized using 0.1 N HCl in absolute 
isopropanol and analyzed spectrophotometrically at 595 nm.  Statistics were 
performed using one-way ANOVA followed by a Newman-Keuls post hoc t-test 
where significance was set at p<0.05.   
 
6.  Alkaline Phosphatase Assay  
To assess whether melatonin modulated alkaline phosphatase (ALP) 
activity, a marker of osteoblast differentiation, ALP levels were measured by 
analyzing the rate of p-nitrophenyl phosphate disodium hexahydrate (pNPP) 
hydrolysis. Briefly, hAMSCs were plated at a density of 3x103 cells/cm2 and 
exposed to (OS-M-) or (OS+M-) for 0, 5, or 10 days or (OS-M-), (OS-M+), 
(OS+M-), (OS+M+) for 10 days.  ALP levels were normalized against cellular 
protein, determined via Pierce BSA assay (Pierce, Rockford, IL).  The pNPP 
product was generated using a p-nitrophenol phosphate stock (Sigma, St. Louis, 
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MO) and analyzed according to the manufacturer’s instructions to produce a 
soluble yellow end product that was analyzed spectrophotometrically. The pNPP 
reaction was then terminated using 1.0 M NaOH and immediately analyzed at 
405 nm on a microplate reader and compared against a standard curve.  
Alkaline phosphatase histochemical stain (Sigma, St. Louis, MO) was 
used to qualitatively detect the presence of alkaline phosphatase activity.  
Sample wells were washed three times with PBS, fixed in 80% methanol, 20% 
citrate working solution for one min, and then washed four times with distilled 
water.  Alkaline phosphatase histochemical stain was then added, with 
incubation in the dark at room temperature for 1 h.  Following staining, the 
samples were washed three times with PBS and viewed with bright field optics. 
The involvement of melatonin receptors was assessed using pertussis 
toxin (60 ng/ml; Sigma, St. Louis, MO), and the melatonin receptor antagonists, 
luzindole (1 µM; Tocris, Ballwin, MO) and 4P-PDOT (1 µM; Tocris).  EGFR 
involvement was assessed using 1.4 nM of an EGFR inhibitor, PD168393 
(Calbiochem, La Jolla, CA).  The role of MEK 1/2 and clathrin-mediated 
endocytosis were assessed using 15 µM of PD98059, a MEK inhibitor 
(Calbiochem, La Jolla, CA) and 100 µM monodansyl cadaverine (MDC) (Sigma, 
St. Louis, MO).  PKA and the involvement of metalloproteinases were assessed 
using KT5720 (60 nM; Sigma) and GM 6001 (27 nM; Calbiochem), respectively.  
All of these antagonists or inhibitors were added to each of the treatment 
conditions for 10 days and ALP activity assessed as described previously.  
Statistics were performed using one-way ANOVA followed by a Newman-Keuls 
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post hoc t-test where significance was set at p<0.05.   
 
7.  Viability Staining 
To ensure that melatonin or the various drugs were not cytotoxic to 
hAMSCs, Live/Dead assays (Molecular Probes, Eugene, OR) were performed for 
each treatment group according to the manufacturer’s instructions.  Live cells are 
distinguished from non-living cells through their esterase activity that converts 
nonfluorescent cell-permeable calcein AM to a green fluorescent calcein.  
Conversely, non-living cells are identified through an ethidium homodimer-1 dye, 
which enters damaged cell membranes and binds to nucleic acids, causing a red 
fluorescence that was visualized using a fluorescent microscope.  The ethidium 
homodimer-1 dye is unable to pass through intact plasma membranes within 
living cells.  Briefly, hAMSCs were plated at a density of 3x103 cells/cm2 and 
exposed to (OS-M-), (OS-M+), (OS+M-), (OS+M+) for 10 days.  Cell viability was 
then assessed as the percent of viable cells relative to the total population.       
 
8.  Western Blot Analysis 
The effect of melatonin on modulating MEK/ERK (1/2) and EGFR 
activation during these differentiation processes was assessed using Western 
blot analysis.  Briefly, hAMSCs were seeded at a density of 3x103 cells/cm2 in T-
75 flasks.  One day after seeding, the cells were washed in sterile PBS and then 
incubated with 10 ml of either (OS-M-), (OS-M+), (OS+M-), or (OS+M+) 
treatment for 10 days.  After the 10 day exposure, the medium was aspirated and 
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the cells were then washed with 10 ml of PBS.  To the monolayer, 250 µl of lysis 
buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% Triton-X 100, 1 mM EDTA, 1 
mM EGTA, and 1X protease inhibitors) were added.  The resulting lysates were 
collected by scraping and then stored at -20°C until further use.   
A BioRad DC protein assay (Bio-Rad, Hercules, CA) was performed on all 
samples to ensure equal loading of protein into each well of a 4-20% gradient 
SDS-PAGE gel (Bio-Rad, Hercules, CA).  After electrophoresis at 200 V, the 
proteins were transferred to PVDF membranes (Millipore, Bedford, MA) 
presoaked in methanol and blocked in 5% nonfat dry milk dissolved in Tris-
buffered Saline (25 mM Tris, pH 7.4, 140 mM NaCl, 2.7 mM KCl) for 1 h at room 
temperature.  Membranes were incubated overnight at 4° C with anti-MEK (1/2) 
(1:10,000; Sigma, St. Louis, MO), anti-MEK-phos (1/2) (1:1,000; Cell Signaling, 
Beverly, MA), anti-ERK (1/2) (1:10,000; Sigma, St. Louis, MO), or anti-ERK-phos 
(1:1,000; Cell Signaling, Beverly, MA).  For EGFR activation, mouse anti-EGFR 
(1 µg/µl; Calbiochem) was used.  Following three washes in PBS, the 
membranes were then exposed to either anti-mouse (EGFR) or anti-rabbit IgG-
HRP-linked secondary antibodies (1:2,000; Amersham Biosciences, Piscataway, 
NJ) for 1 h.  Unbound secondary antibody was washed away with PBS, and the 
blots were developed using ECL-PLUS (Amersham Biosciences) for 5 min to 
visualize the protein bands.  The blots were exposed to Kodak BioMax Light film 
(Fisher Scientific), developed using a Kodak M35A X-OMAT processor, and 
quantified using NIH Image densitometry software.  All data were normalized 
against cells incubated with basal growth medium and vehicle (OS-M-) or 
  
32
osteogenic medium and vehicle (OS+M-) and analyzed for statistical significance 
(p<0.05) by an unpaired t-test or by one-way ANOVA followed by a Newman-
Keul post hoc t-test.    
 
9.  Nuclear/Cytosol Fractionation 
Nuclear and cytosolic fractions were separated as previously described 
[93].  Following vehicle or melatonin treatment, cells were washed with 1 x PBS 
and scraped into 500 µl of lift buffer  [50 mM β glycerophosphate, 1 mM DTT, 1 
mM EDTA, 1.5 mM EGTA, 1 mM Na3VO4, containing 1 X complete mini protease 
inhibitors (Roche Diagnostics, Mannheim, Germany)].  The cells were then 
centrifuged (12,000 x g, 5 min, 4°C) and the resulting supernatant was discarded 
while the pellet was resuspended in 200 µl of lysis buffer (40 mM β 
glycerophosphate, 1 mM DTT, 10 mM EGTA, 20 mM HEPES, 2 mM Na3VO4, 
1.0% Nonidet P-40).  The lysate was mixed vigorously (10 sec) and then 
centrifuged (12,000 x g, 5 min, 4°C).  The supernatant, representing the cytosolic 
fraction, was separated from the pellet which represented the nuclear fraction.  
To extract the nuclear proteins from the pellet, 100 µl of nuclear extraction buffer 
(50 mM β glycerophosphate, 1 mM DTT, 200 µM EDTA, 25% glycerol, 1.5 mM 
MgCl2, 420 mM NaCl, 500 µM Na3VO4) was added to the pellet, sonicated (2 x 5 
sec, 40 W, 4°C), vortexed (10 sec) and centrifuged (12,000 x g, 5 min, 4°C).  The 
purity of the nuclear fraction was determined by DAPI staining (Invitrogen, 
Carlsdad, CA) for nucleic acids.  To evaluate melatonin’s effect on ERK 
translocation or activation (ERK-P) within the cytoplasm or nucleus, equal 
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amounts of protein were loaded onto a 4-20% gradient acrylamide gel and 
subjected to Western blot analysis.  Total ERK and ERK-P levels were detected 
using anti-ERK (1:10,000, Sigma, St. Louis, MO) or anti-ERK-P (1:1,000, Cell 
Signaling, Beverly, MA) antibodies, respectively.  Proteins were visualized by 
ECL and the bands were quantified by densitometry using NIH Image software.  
Each bar represents the mean ± SEM of 5-6 experiments. All data were analyzed 
by one-way ANOVA followed by a Newman-Keuls post hoc t-test where 
significance was defined as p<0.05 
 
10.  Immunoprecipitation 
 Cells were incubated with OS+ medium for 10 days.  The medium was 
then aspirated and washed with 1X PBS.  Lift buffer (4 ml) consisting of (10 mM 
KPO4, 1 mM EDTA at pH 7.4) was then added to each plate for 5 min and 
centrifuged (500 x g, 3 min).  Five hundred microliters of buffer A (0.5 M EDTA, 
12 mM MgCl2, 1 M Tris containing 1 X complete mini protease inhibitors (Roche 
Diagnostics, Mannheim, Germany)) was added to the resulting pellet, 
homogenized (2 x 15 second, 30,000 rpm, 4°C) and centrifuged (1,800 x g, 30 
min).  A 1% digitonin (Sigma, St. Louis, MO) solution was added (495 µl) to the 
resulting pellet and resuspended.   Five microliters of vehicle (0.05% ethanol), 
0.1 µM melatonin, or 0.1 µM melatonin + 100.0 µM luzindole were added to 
separate reactions, vortexed, and incubated at 4°C for 3 h.  The solutions were 
then centrifuged (12,000 x g, 5 min).  Buffer A (495 µl) and 5 µl of vehicle, 0.1 µM 
melatonin, or 0.1 µM melatonin + 100.0 µM luzindole were added to the resulting 
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supernatants and vortexed.  Ten microliters of rabbit anti-human MT1 or MT2 
melatonin receptor primary antibody (1:2,000) was then added to each solution 
and rocked at 4°C for 12 h.  Protein A agarose beads (50 µl) (Sigma, St. Louis, 
MO) were added to the solutions and incubated at 4°C for an additional 6 h.  
Solutions were then centrifuged (12,000 x g, 5 min).  Ten microliters of 100 µM 
GppNHp (Sigma, St. Louis, MO) and an additional 50 µl protein A agarose beads 
were added to each solution, vortexed, and incubated at 37°C for 1 h to uncouple 
the receptors from their G-proteins.  The solutions were then centrifuged (12,000 
x g, 1 min).  The supernatant, containing the proteins associated with each of the 
melatonin receptors, and the pellet, containing the melatonin receptor IgG 
complex were separated.  Fifteen percent trichloroacetic acid (Sigma, St. Louis, 
MO) was added to the supernatant fraction to precipitate out the proteins in the 
cytosol and incubated at 4°C for 5 min.  The supernatant was then centrifuged 
(12,000 x g, 1 min) and an equal volume of SDS sample buffer (0.2% 
bromophenol blue, 200 mM DTT, 20% glycerol, 4% SDS, 100 mM Tris Cl) was 
added to the resulting pellet.  Pellets were subjected to electrophoresis and 
Western blot as described to visualize the MT1 or MT2 melatonin receptor, Gαi-2 
(1:2000, Santa Cruz Biotechnology, Santa Cruz, CA), β-arrestin-1 (1:200, Santa 
Cruz Biotechnology, Santa Cruz, CA), β-arrestin-2 (1:200, Santa Cruz 
Biotechnology, Santa Cruz, CA), EGFR (1:500, Lab Vision, Fremont, CA), MEK 
(1:10,000 Sigma, St. Louis, MO) or ERK (1:10,000 Sigma, St. Louis, MO).   Each 
protein band was normalized against the total amount of melatonin receptor 
immunoprecipitated.  All data were analyzed by one-way ANOVA followed by a 
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Newman-Keuls post hoc t-test where significance was defined as p<0.05.  
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III.  RESULTS AND DISCUSSION 
 
A.  Results 
1.  The effect of osteogenic medium on ALP activity in hAMSCs   
ALP activity was measured as a marker for hAMSC differentiation into 
osteoblasts.  A time-dependent effect of osteogenic medium on ALP activity was 
observed.  ALP activity was detected by day 5 of (OS+)-treatment that reached 
significance by day 10 (Fig. 1).  The 10-day time point was thus chosen because 
it was at this point where significant increases in ALP activity occurred and prior 
to the deposition of significant amounts of calcium [84].    
 
2.  The effect of melatonin and osteogenic medium on ALP activity in 
hAMSCs 
As shown in figure 2, ALP activity increased in hAMSCs following a 10-
day incubation in osteogenic medium supplemented with vehicle (OS+M-) or 
melatonin (OS+M+) when compared to cells exposed to growth medium 
containing vehicle (OS-M-) or melatonin (OS-M+).  Melatonin (50 nM), added to 
the basal growth medium (OS-M+), did not significantly increase ALP activity 
compared to cells exposed to vehicle (OS-M-) alone.  However, when hAMSCs 
were exposed to melatonin, in combination with the osteogenic medium 
(OS+M+), ALP activity significantly (p<0.05) increased beyond that of cells 
exposed to osteogenic medium alone (OS+M-).  These data indicate that 
melatonin enhances ALP activity in hAMSCs when osteogenic medium is present 
(Fig. 2).    
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Figure 1:  The effect of osteogenic medium on ALP activity in hAMSCs.   
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Figure 1:  The effect of osteogenic medium on ALP activity in hAMSCs.  
Cells were seeded at a density of 3000 cells/cm2 in 12-well dishes and cultured 
in growth medium (OS-) in the absence of melatonin (OS-M-) or in osteogenic 
medium (OS+) in the absence of melatonin (OS+M-) for 0, 5, or 10 days.  
Following the exposure period, cells were assayed for ALP activity.  As shown, 
there was a significant increase in ALP activity when cells were exposed to 
osteogenic medium (OS+M-) for 10 days compared to cells cultured in growth 
medium (OS-M-) for 5 or 10 days.  Additionally, there was a significant increase 
in ALP activity in cells exposed to OS+M- treatment for 10 days compared to 5 
days.  Each bar represents the mean ± SEM of 3 experiments.   All data were 
analyzed by one-way ANOVA (F = 12.81; 4, 9 df; p < 0.001) followed by a 
Newman-Keuls post hoc t-test where significance was defined as p < 0.05, where 
a = p < 0.05 when compared to OS-M- (5); b = p < 0.05 when compared to OS-
M- (10); c = P < 0.05 when compared to OS+M- (5).  
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Figure 2: The effect of melatonin and osteogenic medium on ALP activity in 
hAMSCs. 
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Figure 2: The effect of melatonin and osteogenic medium on ALP activity in 
hAMSCs. Cells were seeded at a density of 3000 cells/cm2 in 12-well dishes and 
cultured in either growth medium (OS-) in the absence (OS-M-) or presence of 
melatonin (OS-M+) or in osteogenic medium (OS+) in the absence (OS+M-) or 
presence of melatonin (OS+M+) for 10 days.  Following the 10- day exposure, 
cells were assayed for ALP activity.  As shown, there was a significant increase 
in ALP activity when cells were exposed to osteogenic medium alone (OS+M-) 
compared to cells cultured in growth medium (OS-M-).  Melatonin, added in 
combination with the osteogenic medium (OS+M+), enhanced further ALP 
activity compared to vehicle-exposed cells.  Melatonin had no effect when added 
to the growth medium alone.  Each bar represents the mean ±   SEM of 14 
experiments performed in duplicate.   All data were analyzed by one-way ANOVA 
(F = 24.75; 3, 52 df; p < 0.0001) followed by a Newman-Keuls post hoc t-test 
where significance was defined as p < 0.05 where a = p < 0.05 when compared 
to OS-M-; b = p < 0.05 when compared to OS-M+; c = P < 0.05 when compared 
to OS+M-. [INSET:  Representative photomicrographs of hAMSCs exposed to 
each treatment and then stained with alkaline phosphatase histochemical stain 
after 10 days to visualize ALP activity.  As shown, the intensity of staining 
increased in cells cultured in osteogenic medium when compared to cells 
cultured in growth medium alone]. 
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3.  The effect of melatonin and osteogenic medium on hAMSCs 
morphology 
To further evaluate osteoblast differentiation, the effect of melatonin and 
osteogenic medium on hAMSC morphology was evaluated.  A striated 
morphology, characteristic of an undifferentiated hAMSC, was uniformly 
observed in cells incubated with either vehicle (OS-M-) or melatonin (OS-M+) 
supplemented to the OS- medium (Figs. 3A & 3B).  This result corresponds with 
the biochemical ALP assay, as melatonin was unable to independently induce 
osteoblast morphology in hAMSCs following 10-day incubation.  Conversely, 
hAMSCs incubated with OS+ medium supplemented with either vehicle (OS+M-) 
or melatonin (OS+M+) induced a cuboidal morphology characteristic of a 
differentiated osteoblast (Figs. 3C & 3D).  An additive effect between melatonin 
and osteogenic medium could not be assessed, as the cuboidal morphology was 
overly apparent in both OS+M- and OS+M+ incubated cells. 
 
4.  The effect of pertussis toxin, luzindole, or 4P-PDOT on ALP activity in 
hAMSCs 
To assess whether these effects of melatonin on ALP activity were 
mediated through melatonin receptors, pertussis toxin, and the non-specific 
melatonin receptor antagonist, luzindole and MT2-selective melatonin receptor 
antagonist 4P-PDOT, were added to the (OS+M-) and (OS+M+) treatments.  
Pertussis toxin (60 ng/ml), luzindole (1 µM) [94] and 4P-PDOT (1 µM) [95] alone 
were without effect on inducing ALP activity over that induced by OS+ (Table 1).   
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Figure 3:  The effect of melatonin and osteogenic medium on hAMSCs 
morphology. 
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Figure 3:  The effect of melatonin and osteogenic medium on hAMSCs 
morphology. Cells were seeded at a density of 3000 cells/cm2 in T-75 flasks and 
then cultured in either growth medium (OS-) in the absence (OS-M-, A.) or 
presence (OS-M+, B.) of melatonin or in osteogenic medium (OS+) in the 
absence (OS+M-, C.) or presence (OS+M+, D.) of melatonin for 10 days.  
Following the 10- day exposure, morphology was assessed at 100X total 
magnification.  As shown, morphology of hAMSCs incubated in OS- medium with 
either vehicle or melatonin appeared striated, characteristic of an undifferentiated 
stem cell, indicating melatonin is unable to independently induce osteoblast 
morphology.  Conversely, hAMSCs incubated in OS+ medium in either vehicle or 
melatonin induced a cuboidal morphology characteristic of a differentiated 
osteoblast.   
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Table 1.  The effect of melatonin receptor antagonists and various 
inhibitors on ALP activity in hAMSCs incubated in osteogenic medium 
containing vehicle (OS+M-) or melatonin (OS+M+).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Vehicle                                             98 ± 11                                             - 
   Melatonin                                               -                                            161 ± 21 a 
+ Pertussis toxin                                  43 ± 15                                        21 ± 20 b 
+ Luzindole                                          71 ± 18                                        86 ± 15 b  
+ 4P-PDOT                                         66 ± 12                                        77 ± 25 b 
+ MDC                                                59 ±   5                                        40 ± 10 b 
+ PD98059 (MEK I)                           41 ± 13                                        50 ±   9 b 
+ PD168393 (EGFR I)                       69 ± 16                                        87 ± 36 b 
                     Average ALP Activity ± SEM 
                                     (% OS+M-) 
           OS+M-                                        OS+M+ 
Treatment 
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Table 1.  The effect of melatonin receptor antagonists and various 
inhibitors on ALP activity in hAMSCs incubated in osteogenic medium 
containing vehicle (OS+M-) or melatonin (OS+M+).  Data represent the mean 
± SEM of 4-14 experiments performed in triplicate.  All data were analyzed by 
one-way ANOVA followed by a Newman-Keuls post hoc t-test where significance 
was defined as p < 0.05, where a = p <0.05 when compared to (OS+M-)-treated 
cells; b = p <0.05 when compared to (OS+M+)-treated cells. 
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However, the melatonin-mediated increase in ALP activity was blocked in 
the presence of these agents, indicating that melatonin enhanced ALP activity 
through melatonin receptors, and most probably, the MT2 melatonin receptor 
(Fig. 4). 
To determine whether melatonin receptors were present in hAMSCs, 
saturation binding analysis was performed using the agonist radioligand 2-[125I]-
iodomelatonin.  Following exposure to basal growth medium (OS-M-) or to 
osteogenic medium (OS+M-), 2-[125I]-iodomelatonin binding sites were detected 
and found not to be significantly different from one another [(OS-M-):  KD = 27 pM 
range of SEM (17-45 pM); Bmax = 2.5 ± 1.0 fmol/mg/protein; (OS+M-): KD = 30 pM 
range of SEM (26-34 pM); Bmax = 3.3 ± 0.4 fmol/mg/protein, n = 5].   However, 
chronic 10-day exposure of hAMSCs to melatonin, in either OS- or OS+ medium, 
resulted in a total loss of detectable specific 2-[125I]-iodomelatonin binding sites. 
To assess whether functional melatonin receptors were present in 
hAMSCs, cAMP accumulation assays were performed.  Concomitant with the  
appearance of 2-[125I]-iodomelatonin binding sites in hAMSCs incubated in 
OS+M- medium, functional melatonin receptors were detected as well.  A 
concentration-dependent decrease in cAMP formation occurred with a potency 
value [IC50 = 0.07 pM range of SEM (0.02-0.2 pM), efficacy at 1 pM melatonin = 
66 ± 4% inhibition), n = 4].  However, hAMSCs incubated in osteogenic medium 
and melatonin (OS+M+) showed no concentration-dependent inhibition of cAMP 
(efficacy at 1 pM melatonin = 12 ± 7% inhibition, n = 4).  These results correlate  
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Figure 4: The effect of pertussis toxin, luzindole, or 4P-PDOT on ALP 
activity in hAMSCs. 
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Figure 4: The effect of pertussis toxin, luzindole, or 4P-PDOT on ALP 
activity in hAMSCs. Cells were seeded at a density of 3000 cells/cm2 in 12-well 
culture dishes and then cultured in melatonin-supplemented osteogenic medium 
(OS+M+) in the absence or presence of pertussis toxin (60 ng/ml), 4P-PDOT (1 
µM), or luzindole (1 µM). Following a 10-day exposure, cells were assayed for 
ALP activity.  As shown, pertussis toxin blocked the enhancing effects of 
melatonin indicating the involvement of Gi/Go proteins.  Furthermore, the 
melatonin receptor antagonists, luzindole and 4P-PDOT, also blocked these 
effects indicating the involvement of melatonin receptors, in particular, MT2 
melatonin receptors. Each bar represents the mean ± SEM of 4-14 experiments 
performed in duplicate. All data were analyzed by one-way ANOVA (F = 5.81; 4, 
40 df; p < 0.001) followed by a Newman-Keuls post hoc t-test where significance 
was defined as p < 0.05, where a = p < 0.05 when compared to OS+M-, b = p < 
0.05 when compared to OS+M+.  Abbreviations:  Ptx = pertussis toxin; Luz = 
luzindole.   
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with the lack of detectable specific 2-[125I]-iodomelatonin binding revealed by the 
saturation analysis.  These data suggest that desensitization of melatonin 
receptors occurred in hAMSCs exposed chronically to melatonin.   
 
 
5.  The effect of melatonin and/or osteogenic medium on hAMSC 
proliferation 
The effects of these various treatments on cellular proliferation of hAMSC 
were assessed because melatonin has been shown to reduce proliferation in a 
variety of cells types [96-104] and also because an attenuation of proliferation is 
usually associated with differentiated cell types [105, 106].  As shown in figure 5, 
melatonin or osteogenic medium alone inhibited proliferation by 11-14% (p<0.05) 
when compared to hAMSCs incubated in growth medium (OS-M-).  Melatonin, 
added to the osteogenic medium, did not further enhance these inhibitory effects.    
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Figure 5:  The effect of melatonin and/or osteogenic medium on hAMSC 
proliferation. 
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Figure 5:  The effect of melatonin and/or osteogenic medium on hAMSC 
proliferation. Cells were seeded at a density of 3000 cells/cm2 in 12-well dishes 
and cultured in either growth medium (OS-) in the absence (OS-M-) or presence 
of melatonin (OS-M+) or in osteogenic medium (OS+) in the absence (OS+M-) or 
presence of melatonin (OS+M+) for 7 days.   After the seventh day of incubation, 
cellular proliferation was assessed using 3-[4,5-dimethylthiazol-2yl]-2,5-
diphenyltetrazolium bromide; thiazolyl blue (MTT) assay.  As shown, a subtle yet 
significant inhibition of cellular proliferation occurred following exposure to 
melatonin alone or to osteogenic medium supplemented with 50 nM melatonin.  
Each bar represents the mean ± SEM of 5-6 experiments performed in 
quadruplicate. All data were analyzed by one-way ANOVA (F = 4.36; 3, 18 df; p < 
0.05) followed by a Newman-Keuls post hoc t-test where significance was 
defined as P < 0.05 where a = p < 0.05 when compared to OS-M-.  
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6.  The effect of a MEK inhibitor, PD98059, an EGF receptor inhibitor, PD 
168393 and (coated pit inhibitor) monodansyl cadaverine on ALP activity in 
hAMSCs 
To investigate some potential mechanisms underlying MT2 melatonin 
receptor-mediated effects on ALP activity, the receptor tyrosine kinase pathway  
and mitogen activated signaling pathways were targeted.  Using selective 
inhibitors of each (1 nM of the selective MEK (1/2) inhibitor, PD98059, and, 1.4 
nM of the EGFR inhibitor, PD168393), their effects on promoting or preventing 
ALP activity in differentiating hAMSCs were assessed. When added alone, these 
inhibitors had no effect when compared to cells exposed to osteogenic medium 
alone (OS+M-) (Table 1).  However, when these inhibitors were added in 
combination with melatonin, they blocked the melatonin-induced increases in 
ALP activity (Fig. 6).   
As proposed by Pierce and co-workers [107], MEK activation by G-protein 
coupled receptors (GPCRs) may be modulated by clathrin-mediated endocytosis.  
Monodansyl cadaverine (MDC), a clathrin-coated pit inhibitor, was added to the 
(OS+M-) and (OS+M+) treatments.  As shown in figure 6 and Table 1, the 
addition of MDC (100 µM) prevented any of the increases in ALP activity induced 
by melatonin.  These data implicate EGFRs, the MEK (1/2) signal transduction 
cascade, as well as clathrin-mediated endocytosis, in modulating melatonin’s 
effect on ALP activity in hAMSCs.     
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Figure 6: The effect of a MEK inhibitor, PD98059, an EGF receptor inhibitor, 
PD 168393 and (coated pit inhibitor) monodansyl cadaverine on ALP 
activity in hAMSCs. 
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Figure 6: The effect of a MEK inhibitor, PD98059, an EGF receptor inhibitor, 
PD 168393 and (coated pit inhibitor) monodansyl cadaverine on ALP 
activity in hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 12-well 
culture dishes and then cultured in melatonin-supplemented osteogenic medium 
(OS+M+) in presence of PD98059 (1 nM), PD 168393 (1.4 nM), or MDC (100 
mM). Following a 10-day exposure, cells were assayed for ALP activity.  As 
shown, all inhibitors blocked the enhancing effects of melatonin indicating the 
involvement of the MEK/ERK signaling cascade, EGF receptor activation and 
clathrin-mediated endocytosis in these processes.  Each bar represents the 
mean ± SEM of 4-14 experiments performed in duplicate. All data were analyzed 
by one-way ANOVA (F = 6.11; 4, 40 df; p < 0.001) followed by a Newman-Keuls 
post hoc t-test where significance was defined a p < 0.05, where a = p < 0.05 
when compared to OS+M-, b = p < 0.05 when compared to OS+M+.  
Abbreviations:  MDC = monodansyl cadaverine; MEK I = MEK inhibitor, 
(PD98059); EGFR I = EGF receptor inhibitor, (PD168393). 
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7.  The effect of an acute exposure to melatonin on EGFR activity in 
hAMSCs 
As shown in figure 6, co-incubation of an EGFR inhibitor with melatonin 
prevented any melatonin-induced enhancement of ALP activity.  To determine if 
an acute exposure to melatonin alone activated EGFRs,  hAMSCs that had 
already been exposed to osteogenic medium (OS+M-) for 10 days were 
rechallenged with 50 nM melatonin (OS+M-/M+).  This treatment (OS+M-) 
previously resulted in high 2-[125I]-iodomelatonin binding and high potency of 
melatonin to inhibit forskolin-induced cAMP accumulation.  As shown in figure 7, 
melatonin exposure for 10 min resulted in a significant increase in EGFR activity 
when compared to cells rechallenged with vehicle alone (OS+M-/M-).    
 
8.  The effect of an acute exposure to melatonin on ERK activity in hAMSCs 
An inhibition of the MEK/ERK (1/2) signal transduction pathway was 
sufficient to block the melatonin-induced osteoblast differentiation in hAMSCs 
(Fig. 6).  To determine if an acute exposure to melatonin activated ERK, western 
blot analysis was performed in hAMSCs exposed to osteogenic medium alone 
(OS+M-).  Again, it was this treatment (OS+M-) that resulted in high 2-[125I]-
iodomelatonin binding and high potency of melatonin to inhibit forskolin-induced 
cAMP accumulation.  Chronic 10-day exposure of hAMSCs to osteogenic 
medium followed by a melatonin rechallenge (OS+M-/M+), resulted in an 
increase in ERK-P without changing total ERK (1/2) expression levels when 
compared to cells rechallenged with vehicle (OS+M-/M-) alone (Fig. 8). 
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Figure 7: The effect of an acute exposure to melatonin on EGFR activity in 
hAMSCs. 
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Figure 7: The effect of an acute exposure to melatonin on EGFR activity in 
hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 10 cm culture 
dishes and then grown in osteogenic medium in the absence of melatonin 
(OS+M-) for 10 days.  Following the 10- day exposure, cells were rechallenged 
with either vehicle (OS+M-/M-) or melatonin (OS+M-/M+) for 10 min and then 
lysed in sample buffer.  EGFR phosphorylation was detected using mouse anti-
EGFR (pTyr1173; 1 mg/ml) followed by anti-mouse IgG-HRP as discussed in the 
Methods.  Proteins were visualized using ECL and the bands were quantified by 
densitometry using NIH Image software.  The bands within an experiment were 
normalized against the OS+M-/M- controls.  As shown, in cells cultured in 
osteogenic medium followed by an acute exposure to melatonin, a significant 
increase in EGFR-P occurred.  Each bar represents the mean ± SEM of 3 
experiments. All data were analyzed by an unpaired t-test (t = 2.44; 6 df; p < 
0.05) where significance a = p < 0.05 when compared to OS+M-/M- [INSET:  A 
representative blot of EGFR-P]. 
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Figure 8: The effect of an acute exposure to melatonin on ERK activity in 
hAMSCs. 
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Figure 8: The effect of an acute exposure to melatonin on ERK activity in 
hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 10 cm culture 
dishes and then grown in osteogenic medium in the absence of melatonin 
(OS+M-) for 10 days.  Following the 10- day exposure, cells were rechallenged 
with either vehicle (OS+M-/M-) or melatonin (OS+M-/M+) for 10 min and then 
lysed in sample buffer.  Equal amounts of protein were loaded onto a 4-20% 
gradient acrylamide gel and subjected to Western blot analysis.  Total ERK and 
ERK-P levels were detected using anti-ERK (1:10,000) or anti-ERK-P (1:1,000) 
antibodies.  Proteins were visualized using ECL and the bands were quantified 
by densitometry using NIH Image software.  The bands within an experiment 
were normalized against the OS+M-/M- controls.   As shown, in cells cultured in 
osteogenic medium followed by an acute exposure to melatonin, a significant 
increase in ERK-P occurred.  No changes in total ERK levels occurred.  Each bar 
represents the mean ± SEM of 3 experiments. All data were analyzed by an 
unpaired t-test (t = 2.80; 9 df; p < 0.05) where significance a = p < 0.05 when 
compared to OS+M-/M- [INSET:  Representative blots of ERK-P (upper blot) and 
ERK (lower blot)]. 
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Cytotoxicity analysis was performed on all treatment groups to ensure that 
the loss in ALP activity was not due to cell death.  Using a live/dead cytotoxicity 
assay, the percent of viable cells relative to control (OS+M+) was unchanged 
[(OS+M-/Ptx) = 149%, (OS+M-/PD98059) = 168%, (OS+M-/MDC) = 103%, 
(OS+M-/PD168393) = 100%, (OS+M-/4P-PDOT) = 96%, and (OS+M-/luzindole) 
= 100%].  These data indicate that the concentrations of inhibitors or antagonists 
used were not cytotoxic to the hAMSCs.  
 
9.  The effect of melatonin and/or osteogenic medium on MEK or ERK 
activity in hAMSCs 
Results from the ALP assays indicated that the MEK (1/2) signal 
transduction pathway was necessary for the melatonin-induced osteoblast 
differentiation.  To assess the chronic effects of melatonin’s exposure on MEK 
and ERK, western blot analysis was performed, analyzing total MEK and ERK 
levels as well as their activation states (i.e, MEK-P and ERK-P).  Chronic 10-day 
exposure of hAMSCs to melatonin and osteogenic medium, resulted in a 
decrease in MEK-P and ERK-P without changing total MEK and ERK (1/2) 
expression levels when compared to (OS+M-)-treated cells.  Melatonin, added to 
growth medium (OS-M+) was without effect on either the activity or expression 
levels of MEK and ERK (Fig. 9).  
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Figure 9: The effect of melatonin and/or osteogenic medium on MEK or 
ERK activity in hAMSCs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OS
-M
-
OS
-M
+
OS
+M
-
OS
+M
+
0
50
100
150
a,b,c
M
EK
-P
/M
EK
(%
O
S-
M
-)
OS
-M
-
OS
-M
+
OS
+M
-
OS
+M
+
0
50
100
150
a,b,c
ER
K
-P
/E
R
K
(%
O
S-
M
-)
MEK 
MEK-P A 
ERK-P
ERK 
B 
  
62
 
Figure 9: The effect of melatonin and/or osteogenic medium on MEK or 
ERK activity in hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 
10 cm culture dishes and then grown in either growth medium in the absence 
(OS-M-) or presence (OS-M+) of melatonin or to osteogenic medium in the 
absence (OS+M-) or presence (OS+M+) of melatonin for 10 days.  Following the 
10- day exposure, cells were lysed in sample buffer.  Equal amounts of protein 
were loaded onto a 4-20% gradient acrylamide gel and subjected to western blot 
analysis.  Total MEK and ERK levels were detected using anti-MEK (1:10,000) or 
anti-ERK (1:10,000) antibodies whereas MEK-P and ERK-P levels were detected 
using anti-MEK-P (1:1,000) or anti-ERK-P (1:1,000) antibodies.  Proteins were 
visualized using ECL and the bands were quantified by densitometry using NIH 
Image software.  The bands within an experiment were normalized against the 
OS-M- controls.  As shown, in cells cultured in osteogenic medium supplemented 
with melatonin (OS+M+), a significant decrease in both MEK-P (A) and ERK-P 
(B) occurred without changes in total levels of these proteins.  Each bar 
represents the mean ± SEM of 3-6 experiments. All data were analyzed by one-
way ANOVA (F = 8.86; 3, 20 df; p < 0.0001) followed by a Newman-Keuls post 
hoc t-test where significance was defined as p<0.05 where a = p < 0.05 when 
compared to OS-M-; b = p < 0.05 when compared to OS-M+ and c = p < 0.05 
when compared to OS+M-. [INSET:  Representative blots of MEK-P (upper blot 
in (A) and MEK lower blot in (A) and ERK-P (upper blot in (B) and ERK (lower 
blot in (B)]. 
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10.  The effects of KT5720, a PKA inhibitor, on ALP activity in hAMSCs 
Melatonin receptors can couple to Gi proteins resulting in decreases in 
PKA [108, 109].  The role of PKA in modulating melatonin-induced increases in 
ALP activity was assessed using a PKA inhibitor, (PKI: KT5720.  As shown in 
figure 10, co-incubation of KT5720 with melatonin and osteogenic medium 
(OS+M+/PKI) did not modulate the melatonin-induced increase in ALP activity 
when compared to (OS+M+)-treated groups.  The inhibitor, when added alone 
(OS+M-/PKI) was not significantly different from (OS-M+)-treated groups.  
 
11.  The effects of GM 6001, a metalloproteinase inhibitor, on ALP activity 
in hAMSCs 
The role of EGFRs in modulating melatonin-induced enhancement of ALP 
activity was further assessed using a metalloproteinase inhibitor, GM 6001.  As 
shown in figure 11, co-incubation of this metalloproteinase inhibitor (MPI) with 
melatonin and osteogenic medium (OS+M+/MPI) blocked any melatonin-induced 
increase in ALP activity when compared to (OS+M+)-treated groups.  In addition, 
this inhibitor, when added alone (OS+M-/MPI) was not significantly different from 
(OS+M-)-treated groups or from cells exposed to growth medium (OS-) alone.  
Thus, unlike the other inhibitors, GM 6001 treatment alone prevented (OS+M-)-
induced increases in ALP activity.  These data show that metalloproteinases 
were essential in ALP activity induced by osteogenic medium alone and perhaps 
melatonin. The role of specific metalloproteinases in modulating melatonin’s 
enhancing effects on ALP activity in differentiating hAMSCs will be defined in 
future studies using selective MPIs. 
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Figure 10: The effect of KT5720, a PKA inhibitor, on ALP activity in 
hAMSCs. 
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Figure 10: The effect of KT5720, a PKA inhibitor, on ALP activity in 
hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 12-well culture 
dishes and then cultured in growth medium (OS-) or osteogenic medium (OS+) 
supplemented with combinations of vehicle (M-), melatonin (M+) or KT 5720 (60 
nM; PKI). Following a 10-day exposure, cells were assayed for ALP activity.  As 
shown, no inhibition of melatonin-enhanced ALP activity was observed in the 
presence of KT 5720 (OS+M+/PKI) when compared to (OS+M+)-treated groups 
suggesting the lack of involvement of PKA in modulating melatonin’s effects on 
ALP activity in hAMSCs.  Each bar represents the mean ± SEM of 4 experiments 
performed in duplicate. All data were analyzed by one-way ANOVA (F = 12.76; 5, 
18 df; p < 0.0001) followed by a Newman-Keuls post hoc t-test where 
significance was defined as p < 0.05, where a = p < 0.05 when compared to OS-
M-, b = p < 0.05 when compared to OS-M+; c = p < 0.05 when compared to 
OS+M-.  Abbreviations:  PKI = PKA inhibitor, KT5720. 
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Figure 11: The effect of GM 6001, a metalloproteinase inhibitor, on ALP 
activity in hAMSCs. 
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Figure 11: The effect of GM 6001, a metalloproteinase inhibitor, on ALP 
activity in hAMSCs. Cells were seeded at a density of 3000 cells/cm2 on 12-well 
culture dishes and then cultured in growth medium (OS-) or osteogenic medium 
(OS+) supplemented with combinations of vehicle (M-), melatonin (M+) or GM 
6001 (27 nM; MPI). Following a 10-day exposure, cells were assayed for ALP 
activity. As shown, co-incubation of GM 6001 with melatonin blocked the 
enhancing effects of melatonin indicating the involvement of the 
metalloproteinase in modulating melatonin’s effects on ALP activity in hAMSCs.  
Each bar represents the mean ± SEM of 4 experiments performed in duplicate. 
All data were analyzed by one-way ANOVA (F = 4.53; 5, 18 df; p < 0.01) followed 
by a Newman-Keuls post hoc t-test where significance was defined a p < 0.05, 
where a = p < 0.05 when compared to OS-M-, b = p < 0.05 when compared to 
OS-M+; c = p < 0.05 when compared to OS+M-; d = p < 0.05 when compared to 
OS+M+.  Abbreviations:  MPI = metalloproteinase inhibitor, GM 6001.  
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12.  ERK-P/ERK translocation patterns in hAMSCs 
The translocation patterns and activity of ERK-P, normalized against total 
ERK protein, was assessed in the cytosol and nuclear fractions of hAMSCs 
stimulated with melatonin during and/or after the 10 day differentiation period.  
The purity of the nuclear fraction was assessed through DAPI staining for nucleic 
acids in both the cytosol and nuclear fractions.  As shown in figure 12, hAMSCs 
incubated with OS+M+ for 10 days and rechallenged with 50 nM melatonin for 10 
min induced a significant enhancement in nuclear ERK-P/ERK activity compared 
to any other treatment group.  A corresponding decrease in ERK-P/ERK protein 
activity was observed in the cytosolic fraction of OS+M+/M+ treated cells.   
Additionally, hAMSCs incubated with OS+M+ and rechallenged with vehicle 
(OS+M+/M-) showed the highest amount of ERK-P/ERK protein activity in the 
cytosol (Fig 12B).  These results indicate that hAMSCs incubated with OS+M+ 
during the 10 day differentiation period remain sensitive to melatonin rechallenge 
(OS+M+/M+) as assessed by nuclear translocation of activated ERK.  
Conversely, hAMSCs incubated with OS+M- during the 10 day differentiation 
period and rechallenged with 50 nM melatonin (OS+M-/M+) did not induce 
activated ERK translocation into the nucleus compared to hAMSCs incubated 
with OS+M- and rechallenged with vehicle (OS+M-/M-), indicating hAMSCs 
require melatonin to be present during the differentiation period to induce 
activated ERK translocation into the nucleus.   
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Figure 12:  ERK-P/ERK translocation patterns in hAMSCs. 
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Figure 12:  ERK-P/ERK translocation patterns in hAMSCs. Cells were seeded 
at a density of 3000 cells/cm2 on 10 cm culture dishes and then grown in 
osteogenic medium with (OS+M+) or without (OS+M-) 50 nM melatonin for 10 
days.  Following the 10- day exposure, cells were rechallenged with either 
vehicle (/M-) or 50 nM melatonin (/M+) for 10 min and the nuclear (A) and 
cytosolic (B) fractions were separated as described.  Equal amounts of protein 
were loaded onto a 4-20% gradient acrylamide gel and subjected to western blot 
analysis.  Total ERK and ERK-P levels were detected using anti-ERK (1:10,000) 
or anti-ERK-P (1:1,000) antibodies.  Proteins were visualized using ECL and the 
bands were quantified by densitometry using NIH Image software.  Each bar 
represents the mean ± SEM of 5-6 experiments. All data were analyzed by one-
way ANOVA (F = 4.07; 3, 18 df; p < 0.05) followed by a Newman-Keuls post hoc 
t-test where significance was defined as p<0.05. 
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13.  Western blot analysis of proteins coupled to the immunoprecipitated 
MT2 receptor expressed in hAMSCs 
Immunoprecipitations of the MT1 and MT2 melatonin receptors and 
subsequent western blot analysis were performed to characterize proteins 
coupled to each receptor to reveal the signaling proteins involved in this 
melatonin-induced osteoblast differentiation process.  Immunoprecipitations of 
the MT1 melatonin receptor expressed in hAMSCs followed by western blot 
revealed no consistent coupling to the EGFR, Giα2, MEK, ERK or β-arrestins 1 
and 2.  This result corresponds with the finding that MT2 melatonin receptors are 
driving these differentiation effects induced by melatonin.  This is also supported 
in our previous findings showing that the MT2 selective antagonist 4P-PDOT 
inhibits melatonin’s ability to enhance ALP activity.  Supporting this is the 
immunoprecipitation data shown in figure 13.  hAMSCs incubated with OS+M- for 
10 days and rechallenged with melatonin (OS+M-/M+) induced a significant 
increase in Giα2, β-arrestin-1, β-arrestin-2, and MEK coupling to MT2 melatonin 
receptors relative to hAMSCs rechallenged with melatonin + luzindole (OS+M-
/M+L), or vehicle (OS+M-/M-).  Melatonin rechallenge did not enhance EGFR or 
ERK coupling to the MT2 receptor relative to vehicle or melatonin + luzindole 
rechallenge.   
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Figure 13:  Western blot analysis of proteins coupled to the  
 
immunoprecipitated MT2 receptor expressed in hAMSCs.   
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Figure 13:  Western blot analysis of proteins coupled to the 
immunoprecipitated MT2 receptor expressed in hAMSCs.  Cells were seeded 
at a density of 3000 cells/cm2 on 10 cm culture dishes and grown in osteogenic 
medium without melatonin (OS+M-) for 10 days.  Following the 10- day exposure, 
cells were rechallenged with 0.1 µM melatonin (/M+), 0.1 µM vehicle (/M-), or 0.1 
µM melatonin + 100.0 µM luzindole (/ML+) for 12 h and the MT2 melatonin 
receptor was immunoprecipitated.  Proteins coupled to the immunoprecipitated 
receptor were assessed via western blot for EGFR (A), Giα2 (B), β-arrestin-1 (C), 
β-arrestin-2 (D), MEK (E), or ERK (F).  Protein bands were quantified by 
densitometry using NIH Image software.  The bands within an experiment were 
normalized against the OS+M-/M- controls.   Each bar represents the mean ± 
SEM of 3 experiments. All data were analyzed by one-way ANOVA (B, F = 5.56; 
2, 6 df; p < 0.05, C, F = 7.35; 2, 6 df; p < 0.05 E, F = 5.64; 2, 6 df; p < 0.05, F, F = 
5.33; 2, 6 df; p < 0.05) followed by a Newman-Keuls post hoc t-test where 
significance was defined as p < 0.05 where a = p < 0.05 when compared to 
OS+M-/M+; b = p < 0.05 when compared to OS+M-/M-.  Abbreviations:  β-Arr.-1 
= β-Arrestin-1, β-Arr.-2 = β-Arrestin-2. 
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B.  Discussion 
 
In this study we showed that melatonin, acting through melatonin 
transmembrane G-protein coupled receptors, enhances hAMSC differentiation 
into osteoblasts, as assessed by an increase in alkaline phosphatase enzymatic 
activity.  The signaling mechanisms mediating melatonin’s ability to enhance 
osteoblast differentiation was dependent on transactivation of EGF receptors and 
subsequent activation of the MAP-K signaling cascade.  Immunoprecipitation of 
activated MT2 receptors demonstrate that β-arrestin is coupled to the receptor, 
where it may play a role in receptor internalization and the formation of 
microdomains with the MAP-K signaling cascade.      
Alkaline phosphatase (ALP) is an essential enzyme produced by 
osteoblasts involved in bone mineralization that can be monitored as an 
osteoblast-associated biomarker to assess osteoblast differentiation [84].  As 
hAMSCs differentiate into mature osteoblasts, ALP production increases [85-87].   
Our data supports the findings of others’ [43, 44], that an osteogenic medium (i.e, 
ascorbate, dexamethasone or β-glycerophosphate) and serum (i.e., growth 
factors), were essential for melatonin’s enhancing effects on ALP activity.  In the 
present study, melatonin did not independently enhance ALP activity with cells 
cultured in growth medium (OS-), but did enhance ALP activity with cells cultured 
in osteogenic medium (OS+).   
Dexamethasone and ascorbate have been reported to independently 
enhance ALP activity in several immature bone progenitor models [110-114].  
Perhaps, melatonin acting through the melatonin receptor and the mitogenic 
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signaling cascade, requires the induction of gene expression mediated through 
the synthetic glucocorticoid dexamethasone to mediate its osteoblast 
differentiation effects.  Dexamethasone has been shown to independently induce 
osteoblast differentiation [113, 114] by acting through the cytosolic glucocorticoid 
receptor α (GRα).  Once activated by dexamethasone, the GRα binds to nuclear 
GR binding elements (GREs) to induce gene expression of Runx2, collagenIα1, 
osteocalcin and ALP necessary for osteoblast differentiation [115, 116].  These 
enhancing effects of melatonin on ALP activity may occur through the mitogenic 
cascade that runs parallel to the GRα signaling pathway and that either (1) 
converges on the same DNA response elements targeted by GRα, or (2) 
activates genes to produce co-activators that then synergize with the regulatory 
elements produced in response to glucocorticoid exposure. Messenger RNA 
transcript levels of these genes implicated in osteoblast differentiation should be 
evaluated to further investigate the additive effect between melatonin and OS+ 
medium.   
Ascorbic acid has additionally been shown to independently enhance ALP 
activity in periodontal ligament cells by enhancing the expression of α2β1 integrin 
receptor and subsequent type I collagen extracellular matrix production [112].  
Melatonin’s inability to enhance ALP activity alone has been previously reported.  
Nakade and colleagues [44], find that serum-free Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with melatonin and 0.01% bovine serum 
albumin, does not significantly enhance ALP production in human bone cells.  
However, Roth and colleagues [43] report that melatonin concentrations as low 
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as 10 nM are able to stimulate ALP gene expression in preosteoblast and rat 
osteoblast-like osteosarcoma cells cultured in growth medium containing FBS, β-
glycerophosphate and ascorbic acid. 
Even though the identity of the melatonin receptor involved in inducing 
osteoblast differentiation in these other models was not determined, in the 
present study, the melatonin-enhancing effects on ALP activity in hAMSCs is 
strongly suspected to have occurred via MT2 melatonin receptors.  The 
involvement of melatonin receptors and Gi proteins in bone-related diseases has 
been documented [49].  Melatonin’s effects on ALP activity seem to occur 
through an enhancement in osteoblast differentiation from pre-existing hAMSCs 
rather than through an increase in osteoblast proliferation, as OS+M+ treatment 
significantly reduces proliferation compared to negative control.   
Typically, a slowing of cell proliferation precedes cellular differentiation 
[117, 118], however, the signaling mechanisms underlying these events are not 
clear.  In many studies, MEK and ERK are implicated in cell proliferation [64, 
119].  In murine MC3T3-E1 osteoblast-like cells, inhibition of MEK using U0126, 
blocks cellular proliferation but not the expression of osteoblastic markers ALP 
and osteocalcin.  However, p38 inhibition by SB203580 blocks the expression of 
osteoblastic markers induced by serum without affecting cellular proliferation.  
The role of JNK in mediating these processes is not clear, but may regulate other 
markers of differentiation including collagen and osteocalcin [64].   Glucocorticoid 
receptors may also be involved.  In mouse MBA-15.4 and human MG-63 
preosteoblastic cell lines, chronic exposure to dexamethasone inhibits cell 
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proliferation and MEK/ERK activity via an up-regulation of MKP-1, a MAP-K 
phosphatase [119].   
Melatonin’s effects on cell proliferation are variable.  Melatonin stimulates 
proliferation in human HOB-M bone cells and SV-HFO human osteoblastic cells 
[45].  In other studies, melatonin produces inhibitory responses in proliferation 
[100, 120].  Biphasic responses to melatonin on cell proliferation have been 
observed [104, 54, 120, 121] that are dependent upon melatonin concentration 
and the cell type examined.  In our study, we observed a subtle, yet significant 
inhibition of cell proliferation in treatment groups containing melatonin, 
osteogenic medium, or both.  The inhibition of proliferation in the (OS+M-) group 
could be mediated through dexamethasone’s and/or melatonin’s inhibitory effects 
on hAMSC proliferation.  We do not believe this (OS+)-induced inhibitory effect 
on proliferation is mediated through the MEK/ERK pathway because hAMSCs 
incubated in osteogenic medium alone (OS+M-) did not show a decrease in 
MEK/ERK activity when compared to cells incubated in growth medium (OS-).  
The only decrease in MEK/ERK activity occurred when cells were cultured in 
osteogenic medium supplemented with melatonin (OS+M+).  These data suggest 
that melatonin modulated this pathway and not factors within the osteogenic 
medium.  Surprisingly, melatonin, when added in combination with osteogenic 
medium (OS+M+) did not further inhibit cellular proliferation when compared to 
(OS+M-)-treated groups.  Perhaps, this level of inhibition was maximal and no 
further decrease in proliferation could occur. 
 The mechanisms underlying osteoblast differentiation are not clear, 
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however, past studies point to a role for the mitogen activated signaling cascade 
in modulating these processes.  A number of recent investigations have 
implicated the p38 mitogen-activated protein kinase [63 - 65, 122] in regulating 
osteoblast differentiation.  Suzuki and colleagues [63] reveal that the p38 specific 
inhibitor, SB203580, almost completely abolishes both ALP production and ALP 
mRNA expression in MC3T3-E1 osteoblast-like cells.  This same group [64] 
show that factors within serum contribute to osteoblastic differentiation, in 
particular, factors that stimulate the MAP-Ks, ERK, p38 and JNK.  Similarly, but 
in other studies, p38 inhibition by SB203580 completely abolishes bone 
morphogenetic protein (BMP)-induced osteocalcin gene expression and matrix 
mineralization in human trabecular bone-derived osteoblasts [122] and 
osteoblast markers in C3H10T1/2 and C2C12 mesenchymal cell lines [65].  
Though not tested, we do not believe that p38 is involved in melatonin-induced 
hAMSC differentiation for two reasons: (1) in past studies, inhibition of p38 MAP-
K does not block ascorbic acid-induced mesenchymal cell differentiation [63], (2) 
ERK-1/2 MAP-K inhibition, but not p38 MAP-K inhibition completely abolishes 
activation of the Runx2 transcription factor involved in controlling osteoblast 
differentiation [123], and (3) an inhibition of ALP activity in the presence of a MEK 
1/2 inhibitor, PD98059, was observed in our system.  Because ascorbate was 
one of the components in our osteogenic medium and ALP activity induced by 
melatonin was completely inhibited by PD98059, the mechanism underlying 
melatonin-induced hAMSC differentiation in the presence of osteogenic medium 
is probably through MEK and ERK and not through p38 MAP-K.  The role of 
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ascorbic acid in inducing ALP activity may be through collagen and the α2β1 
integrin receptor [63]. 
Besides the present study, others show that the extracellular signal-
related kinase (ERK) [65, 66, 124, 125] and Gi proteins [107, 125] are involved in 
osteoblast differentiation.  For example, in one study using bone morphogenic 
protein (BMP) to induce osteoblast differentiation of a mesenchymal progenitor 
cell line (3H10T1/2), it is shown that BMP-2 induces the expression of ERK 1 and 
2, which is blocked in a cell line expressing a dominant negative form of ERK 2 
[66].   In another study using transfected cell models, it is shown that the addition 
of pertussis toxin blocks isoproterenol-induced or UK14303-induced activation of 
ERK mediated through α2ARs or β2AARs, respectively [107].  Likewise, in human 
fetal CRL-11372 preosteoblastic cells, ultrasound-induced activation of ERK and 
the osteoblastic markers, Cbfa1/Runx2 and osteocalcin, are shown to be 
pertussis toxin sensitive [125].   
In our study, acute melatonin exposure increased ERK activity while 
reduced activity levels of both MEK and ERK 1/2 were observed when hAMSCs 
were exposed chronically to melatonin.  Fully desensitized melatonin receptors 
may explain these dual effects in ERK activity.  The fact that MEK inhibition also 
blocked the melatonin-induced increases in ALP activity back to (OS+M-)-treated 
levels, suggested MEK activation at the earlier stages of osteoblastic 
differentiation was essential for these melatonin-enhancing effects.  As normal 
functioning melatonin receptors couple to an inhibition of adenylyl cyclase via Gi 
proteins and activate ERK, then a lack of a decrease in cAMP and PKA activity, 
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due to desensitization of this pathway, should inhibit MEK/ERK signaling. In 
some models of cellular differentiation, cAMP does play a role [68], while in 
others, it does not [65, 71].  Most notably, in murine osteoblasts, PGE2, cholera 
toxin, or forskolin-mediated adenylyl cyclase activation fails to significantly 
enhance ERK 1/2 phosphorylation despite robust increases in intracellular cAMP 
[71].  Cyclic AMP-dependent mechanisms were similarly not involved in the 
melatonin enhancement of ALP activity in hAMSCs differentiated into osteoblasts 
because an inhibition of PKA by KT5720 did not modulate melatonin’s enhancing 
effects.   
The role that EGFRs and clathrin-mediated endocytosis play in modulating 
hAMSC differentiation into an osteoblast may be via their effects on MEK and 
ERK.  In our study, acute melatonin exposure increased EGFR activity whereas 
an inhibition of EGFR activation during the differentiation process blocked any of 
melatonin’s enhancing effects on ALP activity.  Also, the metalloproteinase 
inhibitor, GM 6001, blocked melatonin’s enhancing effects probably by 
preventing HB-EGF shedding and EGFR activation. In a previous study using 
transfected cell models, it is shown that EGFR transactivation by two different 
GPCRs, the α2AAR and the β2AR, occurs.  In addition, it is shown that both 
transactivation and internalization of EGFRs needs to occur in order for ERK 1/2 
to be activated by either one of these receptors [107].   Similarly, but in PC12 
cells, Piiper and colleagues [68] demonstrate that cAMP or forskolin-induced 
ERK 1/2 phosphorylation is blocked in the presence of an EGFR tyrosine kinase 
inhibitor, PD168393 implicating the importance of EGFR activation in modulating 
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MEK and ERK activity in these cells.  Perhaps most compelling, hAMSC 
exposure to EGF but not PDGF, enhances both alkaline phosphatase activity 
and in vitro mineralization following 2-4 d and 9-12 d respectful exposures [67].  
Similar to Piiper’s findings, co-exposure of EGF with the MAP-K inhibitor U0126 
completely inhibits the phosphorylation of ERK1 and ERk2, and completely 
abolishes the hAMSCs ability to differentiate into the osteoblast. 
The mechanism(s) underlying EGFR transactivation by GPCRs may 
involve G-proteins [126, 127].  In COS-7 cells, activation of either endogenously-
expressed LPA receptors by lysophosphatidic acid, or transiently transfected 
α2AARs by UK14304, induces the activation of EGFRs [126].  In this same study, 
it is shown that Gβγ induces this phosphorylation of EGFRs through the adapter 
proteins, Shc and Grb2 [126].  Once activated, these adapter proteins interact 
with the intracellular SH2 domain of the EGFR to induce the recruitment of the 
guanine nucleotide releasing factor Sos to the plasma transmembrane.  Once 
translocated to the membrane, Sos comes in close proximity to the small G-
protein Ras, where it stimulates the exchange of GTP for GDP [128].  Once 
activated, Ras interacts with several effector proteins including Raf, inducing the 
activation of the MAP-K signaling cascade.  More recently, and in an elegant set 
of experiments, it is shown that PTH-induced activation of ERK in cultured 
murine osteoblasts requires EGFR transactivation by promoting the release of 
EGF-like peptides through metalloproteinases [127].  Also, EGF and EGFRs 
have been shown to play an important role in bone development in transgenic 
mice [129-131].  Taken together, these studies show that GPCRs can modulate 
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MEK and ERK1/2 activity in some cells through pertussis toxin sensitive G-
proteins and requires both EGFR activation and internalization.  
Our study revealed that melatonin’s enhancing effects on ALP activity in 
differentiating hAMSCs into osteoblasts is dependent upon clathrin-mediated 
endocytosis, MT2 melatonin receptors, EGFRs, pertussis toxin-sensitive G-
proteins, MEK 1/2 and, perhaps, metalloproteinases. How all of these proteins 
and events can be involved in this differentiation process can be best explained 
by an intriguing hypothesis put forth in a review [132] and as shown in Fig. 13.  In 
this review, it is proposed that MEK and ERK (1/2) activity can be modulated by 
GPCRs via β-arrestin scaffolds and transactivation of EGFRs by 
metalloproteinases forming a scaffolding chain.  The clathrin-mediated 
endocytosis is thought to occur to bring together these signaling components 
forming microdomains, which ultimately result in MEK/ERK 1/2 activation.  This is 
thought to occur following the activation and phosphorylation of GPCRs by 
agonist and β-arrestin binding as well as Gβγ-mediated activation of 
metalloproteinases resulting in HB-EGF shedding and activation of EGFR.  
Perhaps, in differentiating hAMSCs exposed chronically to melatonin, scaffolds 
between phosphorylated and desensitized MT2 melatonin receptors and β-
arrestin are formed bringing together a signaling chain that results in the 
activation of ERK.  Activated ERK can then translocate to various parts of the cell 
and modulate the activity of, as yet unidentified, proteins involved in cellular 
differentiation (Fig. 13).  Additionally, the melatonin enhancing effects on ALP 
activity occurred when melatonin receptors were fully desensitized, implying that 
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MT2 melatonin receptor desensitization is a necessary step in hAMSC 
differentiation into an osteoblast.   A further characterization into the mechanisms 
underlying melatonin receptor desensitization will form the basis of future 
experiments.  In addition, the effects of melatonin on hAMSC differentiation at the 
different stages of osteoblast development will also be examined.   
Findings from the MT2 immunoprecipitation studies support the 
involvement of G-proteins, β-arrestin, and MEK proteins in the melatonin receptor 
microdomain complex following agonist exposure.  As expected, activation of the 
MT2 receptor by melatonin resulted in an enhanced coupling to Giα2 proteins.  
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Figure 14:  Schematic representing melatonin-induced enhancement of 
ALP activity.   
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Figure 14:  Schematic representing melatonin-induced enhancement of 
ALP activity.  Prolonged melatonin exposure induces homologous GRK-
mediated phosphorylation of the MT2 receptor, with subsequent β-arrestin 
binding, and clathrin-dependent receptor internalization.  Once internalized, β-
arrestin scaffolds to the MAP-K pathway.  Additionally, Gβγ-mediated activation of 
matrix metalloproteinases activates the EGF receptor and MAP-K pathway.    
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These results, coupled with the observation that pertussis toxin co-exposure 
abolished melatonin’s ability to enhance ALP activity, strongly implicate the G 
proteins involvement in osteoblast differentiation.  Future research should 
evaluate Gβγ involvement in the osteoblast differentiation process, through the 
use of Gβγ-specific inhibitors (GRK2-ct), or western blot assessment of the Gβγ 
protein coupled to the immunoprecipitated MT2 receptor. 
Agonist-dependent increases in β-Arrestin-1 and β-arrestin-2 binding to 
the immunoprecipitated MT2 melatonin receptor indicate the proteins’ ability to 
form microdomains with the receptor.  While both β-arrestin isoforms associate 
with the MT2 melatonin receptor in an agonist-dependent manner, each protein 
may not have equal ability to form microdomains with the MAP-K signaling 
cascade.  Previous research from Luttrell and colleagues [133] similarly indicate 
that β-arrestin-2 scaffolds bind to stimulated angiotensin II 1a receptors (AT1aR) 
and facilitates the assembly of the cRaf-1, MEK-1, and ERK2 microdomain.  Our 
results show an agonist-mediated enhancement in MEK, but not ERK coupling to 
the immunoprecipitated MT2 receptor.  Perhaps in hAMSCs, upstream MEK 
proteins couple with the β-arrestin-MT2 receptor microdomains to facilitate further 
downstream, uncoupled ERK activation.  Despite the lack of agonist-dependent 
coupling to the microdomain complex, ERK phosphorylation is significantly 
enhanced in hAMSCs acutely treated with melatonin, indicating a modulation of 
ERK activity by the upstream microdomains.  Additionally, considering that MDC 
prevented melatonin’s ability to enhance ALP activity suggests that clathrin-
mediated internalization processes are essential in effecting these processes. 
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The immunoprecipitation results also provide further support for the requirement 
of internalized receptors and the β-arrestin-mediated scaffolding domains to 
activate the MAP-K signaling pathway.  These findings may explain the 
observation that desensitized melatonin receptors significantly enhanced ALP 
activity during the differentiation process.  Following chronic melatonin stimulus, 
β-arrestin coupling to the receptor is enhanced, whereupon the Giα and MEK 
proteins necessary to induce osteoblast differentiation are assembled into a 
scaffolding microdomain that facilitates enhanced signaling efficiency.  β-arrestin 
siRNA constructs should be utilized to further evaluate whether these assembled 
microdomain complexes enhance osteoblast differentiation in the hAMSC.   
Further evidence supporting increased signaling efficiency in β-arrestin-
bound melatonin receptors was observed during assessment of ERK 
translocation.  Interestingly, hAMSC exposed to OS+M+ treatment during the 10 
day differentiation period and re-challenged with melatonin (OS+M+/M+) induced 
a significant increase in ERK-P activity within the nucleus, with a concomitant 
decrease in ERK-P activity in the cytosol.  Similar ERK-P nuclear translocation 
patterns were not observed in hAMSCs differentiated in osteogenic medium 
containing vehicle followed by a melatonin rechallenge (OS+M-/M+).  These 
translocation results support the notion that internalized melatonin receptors, 
coupled with β-arrestin scaffolding microdomains, facilitate melatonin intracellular 
responses.  Perhaps phosphorylated ERK nuclear translocation indicates 
transient β-arrestin binding to the MT2 receptor, as stable β-arrestin binding with 
the activated receptor is associated with cytosolic retention of activated ERK 
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levels [79].  In transfected COS-7 cells, it is shown that increased cytosolic 
translocation of ERK-P induces a more robust mitogenic response, proposedly 
by phosphorylating cytosolic kinases such as p90 RSK involved in transcriptional 
regulation.  Accordingly, the melatonin-mediated reduction in cytosolic ERK-P 
may explain the observed attenuation in hAMSC proliferation.  β-Arrestin’s ability 
to enhance the nuclear translocation of ERK-P protein has been reported [74]. 
Isoproterenol treated COS-7 cells, transfected with the β2-adrenergic receptors, 
causes a significantly higher amount of nuclear ERK-P present in cells 
expressing β-arrestin-2.  The physiological consequence of increased ERK-P 
levels in the nucleus is uncertain in hAMSCs, but may serve to activate Runx2, 
osterix and/or Egr-1; nuclear transcriptional factors that modulate hAMSC 
differentiation into the osteoblast [123, 134-137].  Considering that activation of 
these nuclear transcription factors has been shown to be essential for the 
differentiation of a fully functional osteoblast, then the enhanced ERK-P 
translocation may ultimately mediate melatonin’s ability to enhance osteoblast 
differentiation from a hAMSC.   
Despite the observations that EGFR activation is necessary for melatonin 
to enhance ALP activity and acute melatonin exposure significantly increases 
EGFR phosphorylation, melatonin exposure did not enhance EGFR coupling to 
the immunoprecipitated MT2 receptor.  These data indicate that EGFRs are not 
physically associated with the β-arrestin scaffolding microdomain.  This finding is 
unique considering past studies have shown agonist stimulation of the β2AR 
causes the formation of a complex containing β2AR, EGFR, β-arrestin-1, and the 
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non-receptor tyrosine kinase c-Srs [132].  Transactivation of the EGFR by 
melatonin may therefore progress independently of the β-arrestin scaffold in 
differentiating hAMSCs through Gβγ-mediated activation of transmembrane 
matrix metalloproteinases.  Two separate results support this theory.  Co-
exposure of hAMSCs with either pertussis toxin or the broad-spectrum matrix 
metalloproteinase inhibited melatonin-mediated enhancement in ALP activity.  By 
catalyzing the ADP-ribosylation of the Gi heterotrimeric proteins, pertussis toxin 
prevents the G protein heterotrimer from interacting with the receptor.  Thus, the 
Gβγ subunit is inhibited from interacting with the matrix metalloproteinase.  
Secondly, inhibition of the matrix metalloproteinase prevents melatonin’s ability to 
enhance ALP activity, perhaps by preventing the liberation of the HG-EGF 
agonist responsible for EGFR activation.  Collectively, these findings indicate that 
the stimulated EGFR may activate the MAP-K protein by assembling β-arrestin 
microdomains, perhaps through the recruitment of adaptor proteins, Shc and 
Sos, and small G-proteins like Ras.   
Overall, the results from this study reveal that melatonin plays a significant 
role in human osteoblast development.  It sheds some novel insight as to the role 
of MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade on 
mediating this process.  Perhaps, therapies targeted at melatonin receptors may 
prove to be effective in preventing osteoporosis. 
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IV.  CONCLUSIONS 
 
 
 Findings from this study support the notion that melatonin enhances bone 
formation through the enhancement of osteoblast differentiation in a clinically 
relevant human adult mesenchymal stem cell line.  While melatonin may also 
enhance bone formation by impeding bone-resorbing osteoclast activity, our 
findings refute claims that melatonin stimulates bone formation independent of 
osteoblasts.  These findings indicate that the decrease in circulating melatonin 
levels with age makes humans more susceptible to osteoporosis formation.  The 
use of melatonin replacement therapy may therefore prove an effective manner 
to retard osteoporosis formation with age.   
 Our results also reinforce the prominent role the mitogen activated protein 
kinase cascade plays in differentiation pathways.  In addition to modulating 
differentiation, the MAP-K pathway has also been reported to regulate 
proliferation.  The observation that prolonged melatonin exposure reduces MAP-
K activation indicates a homeostasis mechanism to regulate the variety of 
essential cellular functions MAP-K modulates.  Additionally, the identification that 
melatonin-mediated enhancement in osteoblast differentiation is dependent upon 
epidermal growth factor receptors but not protein kinase A activation identifies 
potential upstream targets of the MAP-K pathway that may have future drug 
design utility.   
 Finally, our results implicate β-arrestin scaffolding to connect components 
of the signaling cascade.  This observation supports a growing body of evidence 
that intermediate agonist exposure, classically thought to induce a waning 
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agonist response, may briefly allow optimal conditions for protein scaffolding and 
subsequent signal transduction.    
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V.  APPENDICIES 
 
A.  Buffers  
 
Western Blot Assay Buffers: 
 
Lysis buffer, pH = 7.5  
  
20 mM Tris-HCl, adjust pH to 7.5  
150 mM NaCl 
1% Triton-X 100 
1 mM EDTA  
1 mM EGTA 
1X protease inhibitors 
 
Add dH20 to 1000 ml, adjust pH to 7.5 
Store at -20°C until further use 
 
2 X SDS loading buffer 
  
0.2% bromophenol blue  
200 mM DTT 
20% glycerol 
4% SDS  
100 mM Tris Cl 
 
Add dH20 to 500 ml, 2 x SDS loading buffer lacking DTT can be stored at 
4°C.  DTT should be added before buffer is to be used.   
 
 
Tris-glycine electrophoresis buffer, pH = 8.3 
 
25 mM Tris 
250 mM glycine  
0.1% SDS 
 
Add dH2O to 1000 ml, adjust pH to 8.3 
Store at 4°C 
 
 
Tris-buffered Saline  
 
25 mM Tris  
140 mM NaCl 
2.7 mM KCl 
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.Add dH2O to 1000 ml, adjust pH to 7.4 
Store at 4°C 
 
Transfer Buffer 
 
39 mM glycine 
48 mM Tris base 
0.037% SDS 
20% methanol 
 
Add dH2O to 1000 ml 
Store at 4°C 
 
 
Nuclear/Cytosol Fractionation: 
 
 
Lift Buffer  
 
50 mM β glycerophosphate 
1 mM DTT  
1 mM EDTA 
1.5 mM EGTA 
1 mM Na3VO4  
1 X complete mini protease inhibitors 
 
Add dH2O to 100 ml     
Store at 4°C 
 
 
Lysis buffer 
  
40 mM β glycerophosphate  
1 mM DTT  
10 mM EGTA  
20 mM HEPES  
2 mM Na3VO4  
1.0% Nonidet P-40 
 
Add dH2O to 100 ml 
Store at 4°C 
 
 
Nuclear Extraction Buffer  
 
50 mM β glycerophosphate  
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1 mM DTT  
200 µM EDTA  
25% glycerol  
1.5 mM MgCl2  
420 mM NaCl  
500 µM Na3VO4 
 
Add dH2O to 500 ml   
Store at 4°C 
 
 
Immunoprecipitation Buffer: 
 
 
Lift buffer, 7.4 
  
10 mM KPO4  
1 mM EDTA  
 
Add dH2O to 500 ml, adjust pH to 7.4 
Store at 4°C 
 
 
Buffer A  
 
0.5 M EDTA  
12 mM MgCl2  
1 M Tris containing  
1 X complete mini protease inhibitors 
 
Add dH2O to 500 ml 
Store at 4°C 
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B.  Alkaline Phosphatase Activity Standard Curve 
 
 
 
 
 
 
 
 
ALP Activity Biochemical Standard Curve 
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C.  Bovine Serum Albumin Protein Standard Curve 
 
 
 
 
 
 
BSA Protein Assay Standard Curve 
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D.  Live/Dead Cytotoxicity Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment (Live/Dead)/OS+M- 
OS+M- 100 
OS+M- PTX 149 
OS+M- LUZ 100 
OS+M- 4P-PDOT 96 
OS+M- MEK I 168 
OS+M- EGFR I 100 
OS+M- MDC 103 
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VII.  ABSTRACT 
 
  
Current osteoporosis therapy is directed toward inhibiting the activity of 
bone-resorbing osteoclasts.  Decreased bone producing osteoblast efficiency 
however, is largely responsible for osteoporosis development.  Therefore, novel 
osteoporosis treatments should stimulate osteoblast formation and activity.  
Accordingly, the purpose of this study was to determine melatonin’s role and 
subsequent mechanism(s) involved in differentiating human adult mesenchymal 
stem cells (hAMSCs) into osteoblasts as assessed by alkaline phosphatase 
activity (ALP) and determine whether receptor compartmentalization facilitates 
these signaling mechanisms.  Melatonin significantly increased osteogenic 
medium-induced alkaline phosphatase activity, an enzyme associated with 
functional osteoblasts, indicating melatonin enhances osteoblast differentiation.   
The mitogen activated protein kinase signaling mechanisms has been implicated 
in osteoblast differentiation.  Based on these findings, we hypothesized that 
melatonin acts through the mitogen activated protein kinase signaling cascade to 
enhance hAMSC differentiation into an osteoblast as assessed by alkaline 
phosphatase activity.  Acute melatonin exposure to hAMSC stimulated 
extracellular regulated kinase (ERK) phosphorylation without affecting total ERK 
protein levels.  Conversely, co-incubation with melatonin and the MEK inhibitor 
PD98059 prevented the melatonin-mediated enhancement in ALP activity in 
hAMSCs.  Taken together, these findings indicate melatonin enhances ALP 
activity via activation of the mitogen activated protein kinase (MAP-K) cascade.  
Protein Kinase A (PKA), epidermal growth factor receptor (EGFR), and matrix 
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metalloproteinase (MMP) activation were evaluated as potential upstream inputs 
of the MAP-K activation.  Subsequent co-incubation of melatonin with specific 
PKA, EGFR, and MMP inhibitors revealed that EGFR and possibly MMP but not 
PKA activate the MAP-K cascade in these cells. The potential for 
compartmentalization of the melatonin receptor and associative signaling 
pathways was assessed by immunoprecipitation analysis.  The MT2 receptor was 
immunprecipitated in the presence of vehicle, melatonin or melatonin + luzindole 
and the pellet was subjected to western blot analysis using antibodies against Gi, 
EGFR, beta arrestin 1,2, MEK and ERK (1/2).  Stem cells exposed to melatonin 
showed that MT2 receptors do complex with Giα2, beta arrestin, and MEK in an 
agonist-dependent manner.  These findings indicate in differentiating hAMSCs 
exposed chronically to melatonin, beta-arrestin scaffolds form with MT2 receptors 
bringing together a signaling chain that may facilitate activation of the MAP-K 
cascade and hence, their differentiation into osteoblasts.      
 
 
